<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-5251-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TECANA 20MG/ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        118.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Actavis Italy SpA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Actavis Italy SpA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX19 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tecana belongs to a group of medicines called cytostatics (anti-cancer medicines).<br />Tecana is used for the treatment of advanced cancer of the colon and rectum in adults, either in a combination with other medicines or alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Tecana</p><ul><li><p>- &nbsp;if you are allergic to irinotecan hydrochloride trihydrate or any of the other ingredients of this medicine (listed in section 6)</p></li><li><p>- &nbsp;if you have any other bowel disease or a history of bowel obstruction</p></li><li><p>- &nbsp;if you are pregnant or breast feeding</p></li><li><p>- &nbsp;if you have increased levels of bilirubin in the blood (more than 3 times the upper</p><p>limit of normal)</p></li><li><p>- &nbsp;if you have severe bone marrow failure</p></li><li><p>- &nbsp;if you are in a poor general health (evaluated by an international standard)</p></li><li><p>- &nbsp;if you are&nbsp;using the natural remedy St Johns&rsquo; Wort (Hypericum perforatum)</p><p>Warnings and precautions</p><p>Talk to your doctor before using Tecana. This medicine is intended for adults only.<br />Special care is needed in older patients.<br />As Tecana is an anti-cancer medicine it will be administered to you in a special unit and under the supervision of a doctor qualified in the use of anti-cancer medicines. The unit&rsquo;s personnel&nbsp;will explain to you what you need to take special care of during and after the treatment. This leaflet may help you to remember that.</p><p>1) The first 24 hours after administration of Tecana</p><p>During administration of Tecana (30-90 min.) and shortly after administration you may experience some of the following symptoms:</p></li></ul><ul><li><p>- &nbsp;diarrhoea</p></li><li><p>- &nbsp;sweating</p></li><li><p>- &nbsp;abdominal pain</p></li><li><p>- &nbsp;watering eyes</p></li><li><p>- &nbsp;visual disturbance</p></li><li><p>- &nbsp;excessive mouth watering</p><p>The medical term for these symptoms is acute cholinergic syndrome which can be treated (with atropine). If you have any of these symptoms immediately tell your doctor who will give you any treatment necessary.</p><p>2) From the day after treatment with Tecana until next treatment</p><p>During this period you may experience various symptoms, which may be serious and require immediate treatment and close supervision.</p><p>Diarrhoea<br />If your diarrhoea starts more than 24 hours after administration of Tecana&nbsp;(&ldquo;delayed diarrhoea&rdquo;) it may be serious. It is often seen about 5&nbsp;days after administration. The diarrhoea should be treated immediately and kept under close supervision. Immediately after the first</p></li></ul><p>liquid stools do the following:</p><p>1. Take any anti-diarrhoeal treatment that the doctor has given you, exactly as he/she has told you. The treatment may not be changed without consulting the doctor. Recommended anti-diarrhoeal treatment is loperamide (4 mg for the first intake and then 2 mg every 2 hours, also during the night). This should be continued for at least 12hours after the last liquid stools. The recommended dosage of loperamide may not be taken for more than 48 hours.</p><p>2 Drink large amounts of water and rehydration fluids, immediately (i.e. water, soda water, fizzy drinks, soup or oral rehydration therapy)</p><p>3. Immediately inform your doctor who is superivsing the treatment, and tell him/her about the diarrhoea. If you are not able to reach the doctor, contact the unit at the hospital supervising the Tecana treatment. It is very important that they are aware of the diarrhoea.</p><p>You must immediately tell the doctor, or the unit supervising the treatment, if:</p><ul><li><p>- &nbsp;you have nausea and vomiting as well as diarrhoea</p></li><li><p>- &nbsp;you have any fever as well as diarrhoea</p></li><li><p>- &nbsp;you still have diarrhoea 48 hours after starting the diarrhoea treatment</p><p>Note!&nbsp;Do not take any treatment for diarrhoea other than that given to you by your doctor and&nbsp;the fluids described above. Follow the doctor&rsquo;s&nbsp;instructions. The anti-diarrhoeal treatment should&nbsp;not&nbsp;be used to prevent a further episode of diarrhoea,, even though you have experienced delayed diarrhoea at previous cycles.</p><p>Fever<br />If the body temperature increases over 38&deg;C it may be a sign of infection, especially if you also have diarrhoea. If you have any fever (over 38&deg;C) contact your doctor or the unit immediately so that they can give you any treatment necessary.</p><p>Nausea and vomiting<br />If you have nausea and/or vomiting contact your doctor or the unit immediately</p><p>Neutropenia</p></li></ul><p><img alt="page2image3582656" width="43.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e3c6d544-9bc3-4e78-861f-36355e46690b" />&nbsp;<img alt="page2image3582272" width="93.504000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0f6f823d-bcc4-4030-bc82-ef20fad81ef9" />&nbsp;<img alt="page2image3578624" width="54.360000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/2609cc75-1fcd-4754-8632-ca091a137cad" /></p><p>Tecana may cause a decrease in the number of some of your white blood cells, which play an important role in fighting infections. This is called neutropenia. Neutropenia is often seen during treatment with Tecana and is reversible. Your doctor should arrange for you to have regular blood tests to monitor these white blood cells. Neutropenia is serious and should be treated immediately and carefully monitored.</p><p>Breathing difficulties<br />If you have any breathing difficulties contact your doctor immediately.</p><p>Impaired liver function<br />Before treatment with Tecana is started and before every following treatment cycle the liver function should be monitored (by blood tests).</p><p>If you have one or more of the symptoms mentioned, after you have returned home from the hospital, you should immediately contact the doctor or the unit supervising the Tecana treatment.</p><p>Impaired kidney function<br />As this medicine has not been tested in patients with kidney problems, please check with your doctor if you have any kidney problems.</p><p>Children</p><p>Irinotecan should not be used in children.</p><p>Other medicines and Tecana</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. This is also valid for herbal medicines, strong vitamins and minerals.<br />Some medicines may alter the effects of Tecana e.g. ketoconazole (for the treatment of fungal infections), rifampicin (for the treatment of tuberculosis) and some medicines for the treatment of epilepsy (carbamazepine, phenobarbital and phenytoin).</p><p>The herbal medicine St John&rsquo;s Wort (Hypericum perforatum) may not be used concurrent with Tecana and not between treatments, as it may decrease the effect of irinotecan.<br />If you require an operation, please tell your doctor or anaesthetist that you are using this medicine, as it may alter the affect of some medicines used during surgery.</p><p>Pregnancy, breast-feeding and fertility</p><p>Tecana must not be used during pregnancy.<br />Women of child-bearing age should avoid becoming pregnant. Contraceptive measures must be taken by both male and female patients during and for at least three months after cessation of therapy. Still, if you become pregnant during this period you must immediately inform your doctor.<br />Breast-feeding must be discontinued for the duration of irinotecan therapy.</p><p>Driving and using machines</p><p>In some cases Tecana may cause side effects which affect the ability to drive and use tools and machines. Contact your doctor or pharmacist if you are unsure.</p><p>During the first 24 hours after administration of Tecana you may feel dizzy or have visual disturbances. If this happens to you do not drive or use any tools or machines.</p><p>Tecana contains sorbitol and sodium.<br />If you suffer from an&nbsp;intolerance to some sugars, tell your doctor before you are given this medicinal product.</p><p><img alt="page3image3808576" width="93.864000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c1144b01-a88a-45d8-b6a4-4f1cef7dd4a8" />&nbsp;<img alt="page3image3808768" width="102.020000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8d921914-9f1e-4cf6-9af3-dd2cffa45e3d" />&nbsp;<img alt="page3image3808960" width="111.860000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/59ac4775-39bb-4409-966e-4a69a3b05265" /></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially&nbsp;&lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tecana will be given as an infusion into your veins over a period of 30-90 minutes. The amount of infusion you are given will depend on your age, size and general medical condition. It will also depend on any other treatment you may have received for your cancer. Your doctor will calculate you body surface area in square meters (m2).</p><ul><li><p>- &nbsp;If you have previously been treated with 5-fluorouracil you will normally be treated with Tecana alone starting with a dose of 350 mg/m2&nbsp;every 3 weeks.</p></li><li><p>- &nbsp;If you have not had previous chemotherapy you will normally receive 180 mg/m2&nbsp;Tecanaevery two weeks. This will be followed by folinic acid and 5-fluorouracil.</p><p>These dosages may be adjusted by your doctor depending on your condition and any side- effects you may have.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these side effects with you and explain the risks and benefits of your treatment.</p><p>Some of these side effects must be treated immediately. These are:</p><ul><li><p>- &nbsp;diarrhoea</p></li><li><p>- &nbsp;a decrease in the number of neutrophil granulocytes, a type of white blood cell, which</p><p>plays an important role in fighting infections.</p></li><li><p>- &nbsp;nausea and vomiting</p></li><li><p>- &nbsp;fever</p></li><li><p>- &nbsp;breathing difficulties (possible symptom of severe allergic reactions)</p><p>Please read instruction described in section&nbsp;&ldquo;Warnings and precautions&rdquo;&nbsp;carefully and follow them if you have any of the side effects listed above.</p><p>Very common (may affect more than 1 in 10 people)</p></li></ul><ul><li><p>- &nbsp;Blood disorders: Neutropenia (decreased number of some white blood cells), thrombocytopenia (decreased number of blood platelets), anaemia.</p></li><li><p>- &nbsp;Delayed diarrhoea.</p></li><li><p>- &nbsp;Hair loss (the hair grows again after end of treatment).</p></li><li><p>- &nbsp;In combination therapy transient serum levels of some enzymes (SGPT, SGOT,</p><p>alkaline phosphatase) or bilirubin.</p><p>Common (may affect up to 1 in 10 people)</p></li></ul><ul><li><p>- &nbsp;Acute cholinergic syndrome: the main symptoms are defined as early diarrhoea and various other symptoms such as abdominal pain; red, sore, itching or weeping eyes (conjunctivitis); running nose (rhinitis); low blood pressure; widening of the blood vessels; sweating, chills; a feeling of general discomfort and illness; dizziness; visual disturbances, pupil contraction; watering eyes and increased salivation, occurring during or within the first 24 hours after the infusion of Tecana.</p></li><li><p>- &nbsp;Infections.</p></li><li><p>- &nbsp;Fever associated with a severe decrease in the number of some white blood cells.</p></li><li><p>- &nbsp;Dehydration, commonly associated with diarrhoea and /or vomiting.</p></li></ul><ul><li><p>- &nbsp;Constipation.</p></li><li><p>- &nbsp;Fatigue.</p></li><li><p>- &nbsp;Increased levels of liver enzymes and creatinine in the blood.</p><p>Uncommon (may affect up to 1 in 100 people)</p></li></ul><ul><li><p>- &nbsp;Allergic reactions.</p></li><li><p>- &nbsp;Mild skin reactions; mild reactions at the infusion site.</p></li><li><p>- &nbsp;Early effects such as breathing difficulties.</p></li><li><p>- &nbsp;Lung disease (interstitial pulmonary disease).</p></li><li><p>- &nbsp;Intestinal blockage.</p></li><li><p>- &nbsp;Gastrointestinal bleeding.</p></li><li><p>- &nbsp;Abdominal pain and inflammation, causing diarrhoea (a condition known as</p><p>pseudomembraneous colitis).</p></li><li><p>- &nbsp;Infrequent cases of renal insufficiency, low blood pressure or cardio-circulatory failure</p><p>have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting or sepsis.</p><p>Rare (may affect up to 1 in 1,000 people)</p></li></ul><ul><li><p>- &nbsp;Severe allergic reactions (anaphylactic/anaphylactoid reactions). If this happens you should tell your doctor immediately</p></li><li><p>- &nbsp;Early effects such as muscular contraction or cramps and numbness (paraesthesia).</p></li><li><p>- &nbsp;Inflammation of the colon including the appendix.</p></li><li><p>- &nbsp;Intestinal perforation; Anorexia; abdominal pain; inflammation of the mucous</p><p>membranes.</p></li><li><p>- &nbsp;Inflammation of the pancreas.</p></li><li><p>- &nbsp;Increased blood pressure during and following administration.</p></li><li><p>- &nbsp;Decreased levels of potassium and sodium in the blood, mostly related to diarrhoea and</p><p>vomiting.</p><p>Very rare (may affect up to 1 in 10,000 people)</p></li></ul><ul><li><p>- &nbsp;Transient speech disorders.</p></li><li><p>- &nbsp;Increase in levels of some digestive enzymes which break down sugars and fats.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353- 2354-2334-2340. Toll free phone: 8002490000. E-mail: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not freeze.<br />For single use only.<br />Keep the vial in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>The product should be diluted and used immediately after opening.<br />If prepared aseptically, the diluted solution can be stored for 24 hours at temperatures up to 30&deg;C and for 48 hours at 2-8&deg;C (e.g. in a fridge).</p><p>Do not be throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Tecana contains</p><ul><li><p>- &nbsp;The active substance is irinotecan hydrochloride trihydrate</p></li><li><p>- &nbsp;1 ml of concentrate contains 20 mg irinotecan hydrochloride trihydrate equivalent to</p><p>17.33 mg of irinotecan.</p></li><li><p>- &nbsp;One 2 ml vial contains 40 mg irinotecan hydrochloride trihydrate.</p></li><li><p>- &nbsp;One 5 ml vial contains 100 mg irinotecan hydrochloride trihydrate.</p></li><li><p>- &nbsp;One 15 ml vial contains 300 mg irinotecan hydrochloride trihydrate.</p></li><li><p>- &nbsp;One 25 ml vial contains 500 mg irinotecan hydrochloride trihydrate.</p></li><li><p>- &nbsp;The other ingredients are sorbitol E420, lactic acid, sodium hydroxide, hydrochloric</p><p>acid and water for injections.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tecana 20 mg/ml concentrate for solution for infusion is a clear, colourless to slightly yellow solution.
Pack size:
1 x 2 ml vial 1 x 5 ml vial 5 x 5 ml vial 1 x 15 ml vial 1 x 25 ml vial
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li><p>Marketing Authorisation Holder</p><p>Tadawi biomedical company Olaya str<br />Riyadh<br />Saudi Arabia</p><p>Actavis Group hf. Reykjavíkurvegi 76-78, IS-220 Hafnarfjör&eth;ur Iceland</p></li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 06/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي هذا الدواء إلى مجموعة أدوية تدعى الأدوية السامة للخلايا (أدوية مضادة للسرطان).&nbsp;</p><p dir="RTL">يُستعمل تيكانا لمعالجة السرطان المتقدم للقولون والشرج لدى البالغين, إما بالمشاركة مع أدوية أخرى أو لوحده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل تيكانا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">- إذا كنت تتحسس من هايدروكلورايد إرينوتيكان ثلاثي الهيدرات أو من أي من المكونات الأخرى لهذا الدواء (المدرجة في البند 6).</p><p dir="RTL">- إذا كنت مصاباً بأي مرض آخر للمعي الغليظ أو كان لديك تاريخ لإنسداد المعي الغليظ.</p><p dir="RTL">- إذا كنتِ حاملاً أو مرضعةً.</p><p dir="RTL">- إذا كانت مستويات البيليروبين متزايدة في الدم (أكثر من ثلاثة أضعاف الحد الأعلى للمستوى الطبيعي).</p><p dir="RTL">- إذا كان لديك فشل شديد في نخاع العظم.</p><p dir="RTL">- إذا كنت بحالة صحية عامة ضعيفة (المقيمة بمعيار دولي).</p><p dir="RTL">- إذا كنت تستعمل العلاج الطبيعي&nbsp;&quot;نبتة القديس جونز&quot; (<em>هيبيريكوم بيرفوراتوم</em>).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إنذارات وتحذيرات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدّث إلى طبيبك أو الصيدلي قبل إستعمال تيكانا. ذلك أن هذا الدواء معد للبالغين فقط. ولا بد من العناية الخاصة لدى المرضى الأكبرالآخرين.</p><p dir="RTL">وحيث أن تيكانا دواء مضاد للسرطان فسوف يتم إعطاؤه إليك في وحدة خاصة وتحت إشراف طبيب مؤهل في إستعمال الأدوية المضادة للسرطان. وسوف يشرح لك العاملون في الوحدة ماذا تحتاج من عناية خاصة أثناء المعالجة وبعدها. ويمكن أن تساعدك هذه النشرة في تذكر ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>1) الساعات الـ 24 الأولى بعد إعطاء تيكانا</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء إعطاء تيكانا (30&ndash;90 دقيقة) وبعد برهة من إعطائه لك ربما ستعاني من بعض الأعراض التالية:</p><p dir="RTL">- إسهال.</p><p dir="RTL">- تعرق.</p><p dir="RTL">- ألم في البطن.</p><p dir="RTL">- عينان دامعتان.</p><p dir="RTL">- إضطراب في البصر.</p><p dir="RTL">- سائل مائي مفرط في الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المُصطلح الطبي لهذه الأعراض هو متلازمة الكوليني الحادة والتي يمكن معالجتها (بالأتروبين). فلإذا كان لديك أي من هذه الأعراض بلّغ طبيبك فوراً وهو سوف يعطيك أية معالجة ضرورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>2) من اليوم التالي للمعالجة بتيكانا حتى المعالجة القادمة</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء هذه الفترة قد تعاني من أعراض مختلفة, والتي ربما تكون خطيرة وتتطلب معالجة فورية وإشرافاً عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإسهال</u></p><p dir="RTL">إذا بدأ الإسهال عندك بعد أكثر من 24 ساعة من إعطائك تيكانا (&quot;إسهال متأخر&quot;) فربما يكون خطيراً. وغالباً ما يُشاهد بعد حوالي خمسة أيام من إعطأء الدواء. ويجب أن يعالج الإسهال فوراً ويوضع تحت الإشراف الشديد. وبعد البراز السائل الأول إفعل فوراً ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if !supportLists]-->1-&nbsp;&nbsp;&nbsp;<!--[endif]-->خذ أي معالجة مضادة للإسهال التي يقدمها لك الطبيب, تماماً كما أخبرك أو أخبرتك. ويمكن لا يمكن تغيير المعالجة بدون إستشارة الطبيب. وإن المعالجة المضادة للإسهال الموصوفة هي لوبيراميد (4 ملغ للمناولة الأولى ومن ثم 2 ملغ كل ساعتين وأيضاً أثناء الليل). ويجب أن يستمر ذلك لمدة 12 ساعة على الأقل بعد البراز السائل الأخير. وقد لا تؤخذ جرعة اللوبيراميد الموصوفة لمدة تزيد عن 48 ساعة.</p><p dir="RTL"><!--[if !supportLists]-->2-&nbsp;&nbsp;&nbsp;<!--[endif]-->إشرب كميات كبيرة من الماء وسوائل الإماهة فوراً (أي: ماء، مياه الصودا، مشروبات غازية، شوربة أو معالجة إماهية فموية).</p><p dir="RTL"><!--[if !supportLists]-->3-&nbsp;&nbsp;&nbsp;<!--[endif]-->بلّغ فوراً طبيبك الذي يشرف على المعالجة وأعلمه أو أعلمها عن الإسهال. وإذا لم تتمكن من الوصول إلى طبيبك, إتصل بالوحدة في المشفى المشرفة على المعالجة بتيكانا. ذلك أن من المهم جداً أن يكونوا على علم بالإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك أن تخبر الطبيب فوراً، أو الوحدة المشرفة على العلاج, إذا:</strong></p><p dir="RTL"><strong>- حدث لك غثيان أو إقياء أو إسهال أيضاً.</strong></p><p dir="RTL"><strong>- كنت مصاباً بحمى وبإسهال أيضاً.</strong></p><p dir="RTL"><strong>- ما زال لديك إسهال بعد 48 ساعة من بدء المعالجة للإسهال.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ملاحظة!</strong>&nbsp;لا تُجري أية معالجة للإسهال غير المعالجة المعطاة لك من طبيبك والسوائل الموصوفة أعلاه. وينبغي التقيد بتعليمات الطبيب. كما ينبغي&nbsp;<strong>عدم</strong>&nbsp;إستعمال المعالجة المضادة للإسهال لمنع حدوث إسهال آخر, حتى وإن أصبت بإسهال متأخر في دورات سابقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>حمى</u></p><p dir="RTL">إذا تجاوزت درجة حرارة الجسم 38 درجة مئوية يمكن أن يكون ذلك مؤشراً لوجود إلتهاب، خاصة إذا كنت مصاباً بالإسهال أيضاً. فإذا كنت مصاباً بأي حمى (فوق 38 درجة مئوية) إتصل بطبيبك أو بالوحدة فوراً حتى يستطيعوا أن يقدموا لك أية معالجة ضرورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غثيان وأقياء</u></p><p dir="RTL">إذا حدث لك غثيان و/أو إقياء إتصل بطبيبك أو بالوحدة فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العدلات</u></p><p dir="RTL">يمكن أن يسبب تيكانا إنخفاضاً بعدد خلايا دمك البضاء, والتي تلعب دوراً هاماً في مكافحة الإلتهابات. ويُدعى ذلك بالعدلات. والعدلات تُشاهد غالباً أثناء المعالجة بتيكانا وهي إنعكاسية. ويجب على طبيبك أن يعمل على إجراء فحوص دورية للدم ليراقب هذه الخلايا الدموية البيضاء. والعدلات خطيرة ويجب معالجتها فوراً ومراقبتها مراقبة شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>صعوبات التنفس</u></p><p dir="RTL">إذا كانت لديك صعوبة بالتنفس إتصل بطبيبك فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>إعتلال في وظيفة الكبد</u></p><p dir="RTL">قبل البدء بالمعالجة بتيكانا وقبل كل دورة لاحقة للمعالجة يجب مراقبة وظيفة الكبد (بفحوص للدم).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك واحد أو أكثر من الأعراض المذكورة، بعد عودتك إلى المنزل من المشفى، يجب أن تتصل بطبيبك فوراً أو بالوحدة المشرفة على المعالجة بتيكانا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>إعتلال وظيفة الكليتين</u></p><p dir="RTL">بما أن هذا الدواء لم يُختبر لدى المرضى المصابين باعتلال بوظائف الكليتين، يرجى التحقق مع طبيبك ممّا إذا كانت لديك أية مشاكل في الكليتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">يجب عدم إستعمال إرينوتيكان للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وتيكانا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أبلغ طبيبك إذا كنت تأخذ, أو أنك أخذت مؤخراً, أو يمكن أن تأخذ أية أدوية أخرى. وهذا يصلح أيضا على أدوية الأعشاب, والفيتامينات والمعادن القوية.</p><p dir="RTL">يمكن أن تغير بعض الأدوية تأثيرات تيكانا، مثل كيتوكونازول (لمعالجة الإلتهابات الفطرية), وريفامبيسين (لمعالجة السل), وبعض الأدوية الخاصة بمعالجة الصرع (كاربامازيبين, فينوباربيتال, وفينيتوين).</p><p dir="RTL">يمكن أن لا يستعمل الدواء العشبي&nbsp;&quot;نبتة القديس جونز&quot; (<em>هيبيريكوم بيرفوراتوم</em>).&nbsp;بالتزامن مع تيكانا وليس بين المعالجات, لأنه قد يقلل من تأثير إرينوتيكان.</p><p dir="RTL">إذا كنت تحتاج لأية عملية, عليك أن تُخبر طبيبك أو طبيب التخدير بأنك تستعمل هذا الدواء, لأنه قد يغير من تأثير بعض الأدوية المستعملة أثناء الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">يجب عدم إستعمال تيكانا أثناء الحمل.</p><p dir="RTL">على النساء اللواتي هنَّ في سن الحمل أن يتجنبن أن يصبحن حاملات. ويجب تناول موانع الحمل من قبل كل من الذكور والإناث المرضى خلال ولمدة ثلاثة أشهر على الأقل بعد توقيف المعالجة. ومع ذلك, إذا أصبحت حاملاً أثناء هذه الفترة يجب عليك أن تُخبري طبيبك فوراً.</p><p dir="RTL">كما يجب توقيف الإرضاع طيلة مدة المعالجة بإرينوتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات وإستعمال الآلات</strong></p><p dir="RTL">في بعض الحالات يمكن أن يسبب تيكانا تأثيرات جانبية تؤثر بالقدرة على قيادة السيارات واستعمال الأدوات والآلات. إتصل بطبيبك أو بالصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن خلال الساعات الـ 24 الأولى بعد إعطاء تيكانا أن تشعر بالدوخة أو باضطرابات في البصر. فإذا حدث لك ذلك لا تقود السيارة أو تستعمل أية أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي تيكانا على سوربيتول وصوديوم.</strong></p><p dir="RTL">إذا كنت تعاني من عدم تحمل بعض السكريات, أخبر طبيبك قبل إعطائك هذا المنتج الدوائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من 1 ملمول صوديوم (23 ملغ) بالجرعة الواحدة، أي: أنه خالٍ جوهرياً من الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يعطى تيكانا كحقنة في أوردتك لمدة 30&ndash;90 دقيقة. وتتوقف كمية الحقن التي تُعطى لك على عمرك, وحجمك وحالتك الطبية العامة. كما تتوقف أيضاً على أية معالجة أخرى قد تكون قمت بها لسرطانك. وسوف يحتسب طبيبك مساحة سطح جسمك بالأمتار المربعة (م2).</p><p dir="RTL">&nbsp;</p><p dir="RTL">- إذا سبق لك أن عولجت بـ 5- فلوروراسيل سوف تعالج عادة بتيكانا وحده مبتدئاً بجرعة تبلغ 350 ملغ/م2 كل 3 أسابيع.</p><p dir="RTL">- إذا لم تعالج في السابق معالجة كيميائية فسوف تتلقى عادة 180 ملغ/م2 من تيكانا كل أسبوعين.&nbsp;وسوف يتبع ذلك بحمض فولينيك و5- فلوروراسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن ضبط هذه الجرعات من قبل طبيبك حسب حالتك وحسب أية تأثيرات جانبية لديك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كسائر الأدوية, يمكن أن يسبب هذا الدواء تأثيرات جانبية, وإن كانت لا تصيب جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يبحث طبيبك هذه التأثيرات الجانبية معك وسوف يوضح المخاطر والفوائد المحتملة لمعالجتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض التأثيرات الجانبية التي يجب أن تعالج فوراً, وهي:</strong></p><p dir="RTL">- إسهال.</p><p dir="RTL">- إنخفاض في عدد الخلايا الحبيبية للعدلات, وهي نوع من الخلايا البيضاء التي تلعب دوراً هاماً في مكافحة الإلتهابات.</p><p dir="RTL">- غثيان وأقياء.</p><p dir="RTL">- حمى.</p><p dir="RTL">- صعوبات في التنفس (عرض محتمل لردود فعل تحسسية شديدة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى أن تقرأ التعليمات المبينة في البند&nbsp;<strong>&quot;إنذارات وتحذيرات&quot;</strong>&nbsp;بكل اهتمام والتقيد بها إذا كان لديك أي من التأثيرات الجانبية المدرجة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جداً (يمكن أن تصيب 1 من 10 من الأشخاص):</strong></p><p dir="RTL">- إضطرابات في الدم: عدلات (انخفاض بعدد بعض خلايا الدم البيضاء)، قلة الصفيحات (إنخفاض في عدد صفيحات الدم)، فقر دم.</p><p dir="RTL">- إسهال متأخر.</p><p dir="RTL">- سقوط الشعر (ينمو الشعر مجدداً بعد الإنتهاء من المعالجة).</p><p dir="RTL">- في المعالجة التشاركية مستويات عابرة لمصل بعض الأنزيمات&nbsp;(SGPT,&nbsp;SGOT, فوسفاتاز قلوي)&nbsp;أو بيليروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>شائعة (يمكن أن تصيب 1 من 10 من الأشخاص):</em></strong></p><p dir="RTL">- متلازمة الكوليني الحاد: الأعراض الرئيسية معرفة على أنها إسهال مبكر وأعراض أخرى مختلفة كألم في البطن, إحمرار, إلتهاب, حكة أو عينان باكيتان (التهاب الملتحمة)، سيلان الأنف, ضغط&nbsp;&nbsp;دم منخفض, توسع في الأوعية الدموية, تعرق, بردية, أو شعور عام بعدم الإرتياح, مرض, دوخة أو إضطرابات في البصر, تقلص في بؤبؤ العين, عينان دامعتان ولعاب متزايد, تحدث أثناء أو في غضون الساعات الـ 24 الأولى بعد حقن تيكانا.</p><p dir="RTL">- التهابات.</p><p dir="RTL">- حمى مترافقة مع إنخفاض شديد في عدد بعض خلايا الدم البيضاء.</p><p dir="RTL">- تجفاف, مترافق عموماً مع إسهال و/أو إقياء.</p><p dir="RTL">- إمساك.</p><p dir="RTL">- إعياء.</p><p dir="RTL">- تزايد مستويات أنزيمات الكبد والكرياتينين في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>غير شائعة (يمكن أن تصيب 1 من 100 من الأشخاص):</em></strong></p><p dir="RTL">- ردود فعل تحسسية.</p><p dir="RTL">- ردود فعل جلدية خفيفة, أو ردود فعل خفيفة في موقع الحقن.</p><p dir="RTL">- تأثيرات مبكرة كصعوبات في التنفس.</p><p dir="RTL">- مرض الرئتين (مرض رئوي فراغي).</p><p dir="RTL">- إنسداد الأمعاء.</p><p dir="RTL">- نزف معدي معوي.</p><p dir="RTL">- ألم في البطن والتهاب, يسبب إسهالاً (حالة تُعرفُ بالتهاب القولون الكاذب).</p><p dir="RTL">- حالات غير متكررة لقصور كلوي, أو ضغط دم منخفض أو فشل القلب والدورة الدموية لوحظ لدى مرضى عانوا من حوادث تجفاف مترافقة مع إسهال و/أو إقياء أو تعفن الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>نادرة (يمكن أن تصيب 1 من 1000 من الأشخاص):</em></strong></p><p dir="RTL">- ردود فعل تحسسية شديدة (ردود فعل مفرطة التحسس). فإذا حدث ذلك أخبر طبيبك فوراً.</p><p dir="RTL">- تأثيرات مبكرة مثل تقلص العضلات أو تشنجات أو خدر (إضطراب الحس).</p><p dir="RTL">- إلتهاب القولون بما في ذلك الزائدة الدودية.</p><p dir="RTL">- ثقب معوي؛ فقدان الشهية؛ ألم في البطن؛ إلتهاب الأغشية المخاطية.</p><p dir="RTL">- إلتهاب البنكرياس.</p><p dir="RTL">- تزايد ضغط الدم أثناء وبعد الإعطاء التالي للدواء<strong>.</strong></p><p dir="RTL">- انخفاض مستويات البوتاسيوم والصوديوم في الدم, ويرتبط ذلك تقريباً بالإسهال والإقياء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جداً (يمكن أن تصيب 1 من 10,000 من الأشخاص):</strong></p><p dir="RTL">- إضطرابات عابرة في التكلم.</p><p dir="RTL">- تزايد في مستويات بعض الأنزيمات الهضمية التي تحل السكريات والشحوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي من التأثيرات الجانبية, تحدّث إلى طبيبك أو إلى الصيدلي. ويشمل ذلك أياً من التأثيرات الجانبية المحتملة غير المدرجة في هذه النشرة. ويمكنك أيضاً أن تبلغ عن التأثيرات الجانبية مباشرة عن طريق المركز الوطني لليقظة الصيدلانية وسلامة الأدوية&nbsp;(NPC):</p><p dir="RTL">966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exts: 2317-2356-2353-2354-2334-2340&nbsp;&nbsp;+</p><p dir="RTL">ويمكنك استعمال الهاتف المجاني&nbsp;&nbsp;&nbsp;80022490000</p><p dir="RTL">والبريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa&nbsp;،</p><p dir="RTL">وبالإبلاغ عن التأثيرات الجانبية يمكن أن تساعد في توفير المزيد من المعلومات عن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أبق هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تجمده.</p><p dir="RTL">للإستعمال لمرة واحدة فقط.</p><p dir="RTL">أبق القارورة في العلبة الخارجية للحماية من الضوء.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ إنتهاء صلاحيته المذكورة على العلبة بعد كلمة&nbsp;EXP. ويشير تاريخ الإنتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب تخفيف المنتج واستعماله فوراً بعد الفتح.</p><p dir="RTL">إذا تم تحضيره على نحو مطهر, يمكن تخزين المحلول المخفف لمدة 24 ساعة بدرجة حرارة حتى 30 درجة مئوية, ولمدة 48 ساعة بدرجة حرارة 2-8 درجات مئوية (على سبيل المثال في البراد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ترمي أية أدوية عن طريق المياه الرئيسية أو عن طريق الفضلات المنزلية, إسأل الصيدلي عن كيفية رمي الأدوية التي لم تعد تستعملها. فهذه التدابير سوف تساعد&nbsp;&nbsp;في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي هايدروكلورايد إرينوتيكان ثلاثي الهيدرات.</p><p dir="RTL">- يحتوي مركب من 1 مل 20 ملغ هايدروكلورايد إرينوتيكان ثلاثي الهيدرات ما يعادل 17,33 ملغ إرينوتيكان.</p><p dir="RTL">- تحتوي قارورة من 2&nbsp;&nbsp;&nbsp;مل 40&nbsp;&nbsp;&nbsp;ملغ هايدروكلورايد إرينوتيكان ثلاثي الهيدرات.</p><p dir="RTL">- تحتوي قارورة من 5&nbsp;&nbsp;&nbsp;مل 100 ملغ هايدروكلورايد إرينوتيكان ثلاثي الهيدرات.</p><p dir="RTL">- تحتوي قارورة من 15 مل 300 ملغ هايدروكلورايد إرينوتيكان ثلاثي الهيدرات.</p><p dir="RTL">- تحتوي قارورة من 25 مل 500 ملغ هايدروكلورايد إرينوتيكان ثلاثي الهيدرات.</p><p dir="RTL">- المكونات الأخرى هي سوربيتول&nbsp;E420, وحمض اللبن, وهايدركسيد الصوديوم, وحمض الهايدروكلوريك, وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن مركب تيكانا 20 ملغ/مل للحل والحقن هو رائق, عديم اللون ومائل إلى الصفرة قليلاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أحجام العلب</strong></p><p dir="RTL">قارورة واحدة تحتوي على 2 مل.</p><p dir="RTL">قارورة واحدة تحتوي على 5 مل.</p><p dir="RTL">خمس قوارير كل قارورة تحتوي على 5 مل.</p><p dir="RTL">قارورة واحدة تحتوي على 15 مل.</p><p dir="RTL">قارورة واحدة تحتوي على 25 مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليست جميع أحجام العلب يمكن تسويقها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تداوي الحيوية الطبية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            6/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tecana 20 mg/ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of concentrate contains 20 mg irinotecan hydrochloride trihydrate equivalent to 17.33 mg/ml irinotecan. Each 2 ml, 5 ml, 15 ml or 25 ml vial of Tecana contains 40 mg, 100 mg, 300 mg or 500 mg of irinotecan hydrochloride trihydrate respectively.
Excipients with known effect: Sorbitol E420
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion:
A clear, colourless to slightly yellow solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications</p><p>Tecana is indicated for the treatment of patients with advanced colorectal cancer:</p><ul><li><p>- &nbsp;in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for</p><p>advanced disease,</p></li><li><p>- &nbsp;as a single agent in patients who have failed an established 5-fluorouracil containing treatment</p><p>regimen.</p><p>Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.</p><p>Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.</p></li></ul><p>&nbsp;</p><ul><li>&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>Recommended dosage<br />In monotherapy (for previously treated patient)</p><p><img alt="page3image3878336" width="40.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f25cef8c-2abc-45b4-a0f2-49de8cd46834" />&nbsp;<img alt="page3image3870272" width="98.040000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d47fe929-067d-4419-82ee-2812dcb2c3ae" /></p><p>The recommended dosage of irinotecan hydrochloride trihydrate is 350 mg/m2 administered as an intravenous infusion over a 30- 90&nbsp;minute period every three weeks (see below &ldquo;Method of administration&rdquo; and section 4.4 and 6.6).</p><p>In combination therapy (for previously untreated patient)</p><p>Safety and efficacy of Tecana in combination with 5-fluorouracil (5FU) and folinic acid (FA) have been assessed with the following schedule (see section 5.1): Tecana plus 5FU/FA in every 2 weeks schedule. The recommended dose of irinotecan hydrochloride trihydrate is 180 mg/m2 administered once every<br />2 weeks as an intravenous infusion over a 30-90 minute period, followed by infusion with folinic acid and 5-fluorouracil.</p><p>For the posology and method of administration of concomitant cetuximab, refer to the product information for this medicinal product.</p><p>Normally, the same dose of Tecana is used as administered in the last cycles of the prior irinotecan- containing regimen. Tecana must not be administered earlier than 1 hour after the end of the cetuximab infusion.</p><p>For the posology and method of administration of bevacizumab, refer to the bevacizumab summary product of characteristics.</p><p>Dosage adjustments</p><p>Tecana should be administered after appropriate recovery of all adverse events to grade 0 or 1 NCI-CTC grading (National Cancer Institute Common Toxicity Criteria) and when treatment-related diarrhoea is fully resolved.</p><p>At the start of a subsequent infusion of therapy, the dose of Tecana, and 5FU when applicable, should be decreased according to the worst grade of adverse events observed in the prior infusion. Treatment should be delayed by 1 to 2 weeks to allow recovery from treatment-related adverse events.</p><p>With the following adverse events a dose reduction of 15 to 20 % should be applied for irinotecan hydrochloride trihydrate and/or 5FU when applicable:</p><ul><li><p>- &nbsp;haematological toxicity (neutropenia grade 4, febrile neutropenia (neutropenia grade 3-4 and fever</p><p>grade 2-4), thrombocytopenia and leukopenia (grade 4)),</p></li><li><p>- &nbsp;non haematological toxicity (grade 3-4).</p><p>Recommendations for dose modifications of cetuximab when administered in combination with irinotecan must be followed according to the product information for this medicinal product.</p><p>Refer to the bevacizumab summary product of characteristics for dose modifications of bevacizumab when administered in combination with Irinotecan/5FU/FA.</p><p>Treatment Duration:</p><p>Treatment with Tecana should be continued until there is an objective progression of the disease or an unacceptable toxicity.</p><p>Special populations</p></li></ul><p><img alt="page4image3870656" width="88.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2e88d7da-e31a-457b-887e-03eaffffa85c" />&nbsp;<img alt="page4image3879680" width="91.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/398162f5-1a2d-47fd-a9da-dfa7cd7932d9" />&nbsp;<img alt="page4image3871424" width="87.120000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8adafce5-86df-4d92-8bdc-e8dd2cc6d545" /></p><p>Patients with impaired hepatic function</p><p>In monotherapy: Blood bilirubin levels (up to 3 times the upper limit of the normal range (ULN)) in patients with performance status&nbsp;&le;&nbsp;2, should determine the starting dose of Tecana. In these patients with hyperbilirubinemia and prothrombin time greater than 50 %, the clearance of irinotecan is decreased (see section 5.2) and therefore the risk of hematotoxicity is increased. Thus, weekly monitoring of complete blood counts should be conducted in this patient population.</p><ul><li><p>- &nbsp;In patients with bilirubin up to 1.5 times the ULN, the recommended dosage of irinotecan hydrochloride trihydrate is 350 mg/m2,</p></li><li><p>- &nbsp;In patients with bilirubin ranging from 1.5 to 3 times the ULN, the recommended dosage of irinotecan hydrochloride trihydrate is 200 mg/m2,</p></li><li><p>- &nbsp;Patients with bilirubin beyond 3 times the ULN should not be treated with Tecana (see section 4.3 and section 4.4).</p><p>No data are available in patients with hepatic impairment treated with Tecana in combination.</p><p>Patients with impaired renal function</p><p>Tecana is not recommended for use in patients with impaired renal function, as studies in this population have not been conducted. (See section 4.4 and section 5.2).</p><p>Older People</p><p>No specific pharmacokinetic studies have been performed in older people. However, the dose should be chosen carefully in this population due to their greater frequency of decreased biological functions. This population should require more intense surveillance (see section 4.4).</p><p>Paediatric population</p><p>Irinotecan should not be used in children. Method of administration</p><p>For adults only. After dilution Tecana solution for infusion should be infused into a peripheral or central vein.</p><p>Tecana is cytotoxic, for information regarding dilution, and special precautions for disposal and other handling see section 6.6.</p><p>Tecana should not be delivered as an intravenous bolus or an intravenous infusion shorter than 30 minutes or longer than 90 minutes.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Chronic inflammatory bowel disease and/or bowel obstruction (see section 4.4).
- Pregnancy and lactation (see section 4.4 and section 4.6).
- Bilirubin > 3 times the ULN (see section 4.4).
- Severe bone marrow failure.
- WHO performance status > 2.
- Concomitant use with St John's Wort (see section 4.5).
 
- For additional contraindications of cetuximab or bevacizumab, refer to the product information for these medicinal products.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Tecana should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.</p><p>Given the nature and incidence of adverse events, Tecana will only be prescribed in the following cases after the expected benefits have been weighted against the possible therapeutic risks:</p><ul><li><p>- &nbsp;in patients presenting a risk factor, particularly those with a WHO performance status = 2.</p></li><li><p>- &nbsp;in the few rare instances where patients are deemed unlikely to observe recommendations regarding</p><p>management of adverse events (need for immediate and prolonged antidiarrhoeal treatment combined with high fluid intake at onset of delayed diarrhoea). Strict hospital supervision is recommended for such patients.</p><p>When Tecana is used in monotherapy, it is usually prescribed with the every-3-week-dosage schedule. However, the weekly-dosage schedule (see section 5.1) may be considered in patients who may need a closer follow-up or who are at particular risk of severe neutropenia.</p><p>Delayed diarrhoea</p><p>Patients should be made aware of the risk of delayed diarrhoea occurring more than 24 hours after the administration of Tecana and at any time before the next cycle. In monotherapy, the median time of onset of the first liquid stool was on day 5 after the infusion of irinotecan hydrochloride trihydrate. Patients should quickly inform their physician of its occurrence and start appropriate therapy immediately.</p><p>Patients with an increased risk of diarrhoea are those who had a previous abdominal/pelvic radiotherapy, those with baseline hyperleucocytosis, those with performance status&nbsp;&ge;&nbsp;2 and women. If not properly treated, diarrhoea can be life-threatening, especially if the patient is concomitantly neutropenic.</p><p>As soon as the first liquid stool occurs, the patient should start drinking large volumes of beverages containing electrolytes and an appropriate antidiarrhoeal therapy must be initiated immediately. This antidiarrhoeal treatment will be prescribed by the department where irinotecan hydrochloride trihydrate has been administered. After discharge from the hospital, the patients should obtain the prescribed drugs so that they can treat the diarrhoea as soon as it occurs. In addition, they must inform their physician or the department administering irinotecan hydrochloride trihydrate when/if diarrhoea is occurring.</p><p>The currently recommended antidiarrhoeal treatment consists of high doses of loperamide (4 mg for the first intake and then 2 mg every 2 hours). This therapy should continue for 12 hours after the last liquid stool and should not be modified. In no instance should loperamide be administered for more than<br />48 consecutive hours at these doses, because of the risk of paralytic ileus, nor for less than 12 hours.</p><p>In addition to the anti-diarrhoeal treatment, a prophylactic broad spectrum antibiotic should be given, when diarrhoea is associated with severe neutropenia (neutrophil count &lt; 500 cells/mm3).</p><p>In addition to the antibiotic treatment, hospitalisation is recommended for management of the diarrhoea, in the following cases:</p></li></ul><ul><li><p>- &nbsp;Diarrhoea associated with fever,</p></li><li><p>- &nbsp;Severe diarrhoea (requiring intravenous hydration),</p></li><li><p>- &nbsp;Diarrhoea persisting beyond 48 hours following the initiation of high-dose loperamide therapy.</p><p>Loperamide should not be given prophylactically, even in patients who experienced delayed diarrhoea at previous cycles.</p><p>In patients who experienced severe diarrhoea, a reduction in dose is recommended for subsequent cycles (see section 4.2).</p><p>Haematology</p><p>Weekly monitoring of complete blood cell counts is recommended during treatment with Tecana. Patients should be aware of the risk of neutropenia and the significance of fever. Febrile neutropenia (temperature &gt; 38&deg;C and neutrophil count&nbsp;&le;&nbsp;1,000 cells/mm3) should be urgently treated in the hospital with broad- spectrum intravenous antibiotics.</p><p>In patients who experienced severe haematological events, a dose reduction is recommended for subsequent administration (see section 4.2).</p><p>There is an increased risk of infections and haematological toxicity in patients with severe diarrhoea. In patients with severe diarrhoea, complete blood cell counts should be performed.</p><p>Liver impairment</p><p>Liver function tests should be performed at baseline and before each cycle.</p><p>Weekly monitoring of complete blood counts should be conducted in patients with bilirubin ranging from 1.5 to 3 times ULN, due to decrease of the clearance of irinotecan (see section 5.2) and thus increasing the risk of hematotoxicity in this population. Tecana should not be administered to patients with a bilirubin<br />&gt; 3 times ULN (see section 4.3).</p><p>Nausea and vomiting</p><p>A prophylactic treatment with antiemetics is recommended before each treatment with Tecana. Nausea and vomiting have been frequently reported. Patients with vomiting associated with delayed diarrhoea should be hospitalised as soon as possible for treatment.</p><p>Acute cholinergic syndrome</p><p>If acute cholinergic syndrome appears (defined as early diarrhoea and various other symptoms such as sweating, abdominal cramping, lacrimation, myosis and salivation), atropine sulphate (250 micrograms subcutaneously) should be administered unless clinically contraindicated (see section 4.8). Caution should be exercised in patients with asthma. In patients who experienced an acute and severe cholinergic syndrome, the use of prophylactic atropine sulphate is recommended with subsequent doses of Tecana.</p><p>Respiratory disorders</p><p>Interstitial pulmonary disease presenting as pulmonary infiltrates is uncommon during Tecana therapy. Interstitial pulmonary disease can be fatal. Risk factors possibly associated with the development of interstitial pulmonary disease include the use of pneumotoxic drugs, radiation therapy and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during Tecana therapy.</p></li></ul><p>Older People</p><p>Due to the greater frequency of decreased biological functions, in particular hepatic function, in olderpatients, dose selection with Tecana should be cautious in this population (see section 4.2).</p><p>Patients with bowel obstruction</p><p>Patients must not be treated with Tecana until resolution of the bowel obstruction (see section 4.3).</p><p>Patients with impaired Renal Function</p><p>Studies in this population have not been conducted. (see section 4.2 and section 5.2).</p><p>Others</p><p>Since Tecana contains sorbitol, it is unsuitable in hereditary fructose intolerance.</p><p>Infrequent cases of renal insufficiency, hypotension or circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting, or sepsis.</p><p>Contraceptive measures must be taken during and for at least three months after cessation of therapy.</p><p>Concomitant administration of Tecana with a strong inhibitor (e.g. ketoconazole) or inducer (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, St John&#39;s Wort) of CYP3A4 may alter the metabolism of Tecana and should be avoided (see section 4.5).</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per does, i.e. is essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Since irinotecan has anticholinesterase activity, drugs with anticholinesterase activity may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarising drugs may be antagonised.</p><p>Several studies have shown that concomitant administration of CYP3A-inducing anticonvulsant drugs (e.g., carbamazepine, phenobarbital or phenytoin) leads to reduced exposure to irinotecan, SN-38 and SN- 38 glucuronide and reduced pharmacodynamic effects. The effects of such anticonvulsant drugs was reflected by a decrease in AUC of SN-38 and SN-38G by 50 % or more. In addition to induction of cytochrome P450 3A enzymes, enhanced glucuronidation and enhanced biliary excretion may play a role in reducing exposure to irinotecan and its metabolites.</p><p>A study has shown that the co-administration of ketoconazole resulted in a decrease in the AUC of APC of 87 % and in an increase in the AUC of SN-38 of 109 % in comparison to irinotecan given alone.</p><p>Caution should be exercised in patients concurrently taking drugs known to inhibit (e.g., ketoconazole) or induce (e.g., rifampicin, carbamazepine, phenobarbital or phenytoin) drug metabolism by cytochrome P450 3A4. Concurrent administration of irinotecan with an inhibitor/inducer of this metabolic pathway may alter the metabolism of irinotecan and should be avoided (see section 4.4).</p><p>In a small pharmacokinetic study (n=5), in which irinotecan 350 mg/m2&nbsp;was co-administered with St. John&#39;s Wort (Hypericum perforatum) 900 mg, a 42 % decrease in the active metabolite of irinotecan, SN-</p><p>38, plasma concentrations was observed. St. John&#39;s Wort decreases SN-38 plasma levels. As a result, St. John&#39;s Wort should not be administered with irinotecan (see section 4.3).</p><p>Coadministration of 5-fluorouracil/folinic acid in the combination regimen does not change the pharmacokinetics of irinotecan.</p><p>There is no evidence that the safety profile of irinotecan is influenced by cetuximab or&nbsp;vice versa.</p><p>In one study, irinotecan concentrations were similar in patients receiving irinotecan /5FU/FA alone and in combination with bevacizumab. Concentrations of SN-38, the active metabolite of irinotecan, were analyzed in a subset of patients (approximately 30 per treatment arm). Concentrations of SN-38 were on average 33 % higher in patients receiving irinotecan /5FU/FA in combination with bevacizumab compared with irinotecan /5FU/FA alone. Due to high inter-patient variability and limited sampling, it is uncertain if the increase in SN-38 levels observed was due to bevacizumab. There was a small increase in diarrhoea and leukopenia adverse events. More dose reductions of irinotecan were reported for patients receiving irinotecan /5FU/FA in combination with bevacizumab.</p><p>Patients who develop severe diarrhoea, leukopenia, or neutropenia with the bevacizumab and irinotecan combination should have irinotecan dose modifications as specified in section 4.2 Posology and method of administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of child-bearing potential</p><p>Women of child-bearing age receiving Tecana should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur (see section 4.3 and section 4.4). Contraceptive measures must be taken by women of child-bearing age, and also by male patients, during and for at least three months after cessation of therapy.</p><p>Pregnancy</p><p>There is no information on the use of irinotecan in pregnant women. Irinotecan has been shown to be embryotoxic, foetotoxic and teratogenic in rabbits and rats. Therefore, Tecana must not be used during pregnancy (see section 4.3 and section 4.4).</p><p>Breastfeeding</p><p>In lactating rats,&nbsp;14C-irinotecan was detected in milk. It is not known whether irinotecan is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breast- feeding must be discontinued for the duration of Tecana therapy (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of Tecana, and advised not to drive or operate machinery if these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects detailed in this section refer to Tecana. There is no evidence that the safety profile of irinotecan is influenced by cetuximab or&nbsp;vice versa. In combination with cetuximab, additional reported undesirable effects were those expected with cetuximab (such as acneform rash 88 %). Therefore also refer to the product information of cetuximab.</p><p>For information on adverse reactions in combination with bevacizumab, refer to the bevacizumab summary product of characteristics.</p><p>The following adverse reactions considered to be possibly or probably related to the administration of irinotecan hydrochloride trihydrate have been reported from 765 patients at the recommended dose of 350 mg/m2 in monotherapy, and from 145 patients treated by irinotecan hydrochloride trihydrate in combination therapy with 5FU/FA in every 2 weeks schedule at the recommended dose of 180 mg/m2.</p><p>Frequency estimate: Very Common (&ge; 1/10); Common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); Uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); Rare (&ge;&nbsp;1/10,000 to &lt; 1/1,000); Very Rare (&lt; 1/10,000)</p><p>Gastrointestinal disorders</p><p>Delayed diarrhoea</p><p>Diarrhoea (occurring more than 24 hours after administration) is a dose-limiting toxicity of Tecana.<br />In monotherapy:<br />Very Common: Severe diarrhoea was observed in 20 % of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 14 % have severe diarrhoea. The median time of onset of the first liquid stool was on day 5 after the infusion of irinotecan hydrochloride trihydrate.</p><p>In combination therapy:<br />Very Common:&nbsp;Severe diarrhoea was observed in 13.1 % of patients who follow recommendations for the management of diarrhoea. Of the evaluable cycles, 3.9 % have severe diarrhoea.</p><p>Uncommon:&nbsp;Cases of pseudo-membranous colitis have been reported, one of which has been documented bacteriologically (Clostridium difficile).</p><p>Nausea and vomiting<br />In monotherapy:<br />Very Common: Nausea and vomiting were severe in approximately 10 % of patients treated with antiemetics.</p><p>In combination therapy:<br />Common:&nbsp;A lower incidence of severe nausea and vomiting was observed (2.1 % and 2.8 % of patients respectively).</p><p>Dehydration<br />Common:&nbsp;Episodes of dehydration associated with diarrhoea and/or vomiting.</p><p>Uncommon:&nbsp;Cases of renal insufficiency, hypotension or cardio-circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhoea and/or vomiting.</p><p>Other gastrointestinal disorders</p><p><img alt="page10image3967424" width="112.680000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/91bc5138-e81f-4f0f-9f14-14262551dc7d" />&nbsp;<img alt="page10image3973952" width="83.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fcbeba39-b352-4bb8-8434-2e2939a3a68a" />&nbsp;<img alt="page10image3964928" width="93.480000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/03d876d9-aab9-4db7-848a-c436e835ed48" />&nbsp;<img alt="page10image3968384" width="55.560000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6c2f985e-8703-4b00-919c-d98ab72ca2b6" />&nbsp;<img alt="page10image3975872" width="141.860000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/084598d3-3f27-4b1e-83cb-dc0f991ad568" /></p><p>Common:&nbsp;Constipation relative to irinotecan and/or loperamide has been observed, shared between :</p><ul><li><p>- &nbsp;in monotherapy: in less than 10 % of patients</p></li><li><p>- &nbsp;in combination therapy: 3.4 % of patients.</p><p>Uncommon: Intestinal obstruction, ileus, or gastrointestinal haemorrhage<br />Rare:&nbsp;Colitis, including typhlitis, ischemic and ulcerative colitis and intestinal perforation.<br />Cases of symptomatic or asymptomatic pancreatitis have been associated with irinotecan therapy. Other mild effects include anorexia, abdominal pain and mucositis.</p><p>Blood and lymphatic system disorders</p><p>Neutropenia is a dose-limiting toxic effect. Neutropenia was reversible and not cumulative; the median day to nadir was 8 days whatever the use in monotherapy or in combination therapy.</p><p>In monotherapy:<br />Very Common:&nbsp;Neutropenia was observed in 78.7 % of patients and was severe (neutrophil count<br />&lt; 500 cells/mm3) in 22.6 % of patients. Of the evaluable cycles, 18 % had a neutrophil count below 1,000 cells/mm3 including 7.6 % with a neutrophil count &lt; 500 cells/mm3. Total recovery was usually reached by day 22.<br />Anaemia was reported in about 58.7 % of patients (8 % with haemoglobin &lt; 80 g/l and 0.9 % with haemoglobin &lt; 65 g/l).</p><p>Common:&nbsp;Fever with severe neutropenia was reported in 6.2 % of patients and in 1.7 % of cycles. Infectious episodes occurred in about 10.3 % of patients (2.5 % of cycles) and were associated with severe neutropenia in about 5.3 % of patients (1.1 % of cycles), and resulted in death in 2 cases. Thrombocytopenia (&lt; 100,000 cells/mm3) was observed in 7.4 % of patients and 1.8 % of cycles with 0.9&nbsp;% with platelets count &le;&nbsp;50,000 cells/mm3&nbsp;and 0.2 % of cycles. Nearly all the patients showed a recovery by day 22.</p><p>In combination therapy:<br />Very Common:&nbsp;Neutropenia was observed in 82.5 % of patients and was severe (neutrophil count<br />&lt; 500 cells/mm3) in 9.8 % of patients. Of the evaluable cycles, 67.3 % had a neutrophil count below 1,000 cells/mm3 including 2.7 % with a neutrophil count &lt; 500 cells/mm3. Total recovery was usually reached within 7-8 days.<br />Anaemia was reported in 97.2 % of patients (2.1 % with haemoglobin &lt; 80 g/l).<br />Thrombocytopenia (&lt; 100,000 cells/mm3) was observed in 32.6 % of patients and 21.8 % of cycles. No severe thrombocytopenia (&lt; 50,000 cells/mm3) has been observed. One case of peripheral thrombocytopenia with antiplatelet antibodies has been reported.</p><p>Common:&nbsp;Fever with severe neutropenia was reported in 3.4 % of patients and in 0.9 % of cycles. Infectious episodes occurred in about 2 % of patients (0.5 % of cycles) and were associated with severe</p><p>neutropenia in about 2.1 % of patients (0.5 % of cycles), and resulted in death in 1 case. Infections and Infestations</p><p>Uncommon: Renal insufficiency, hypotension or cardio-circulatory failure have been observed in patients who experienced sepsis.</p></li></ul><p><img alt="page11image3877568" width="168.740000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/747ba337-f47e-4fbb-9d96-836fbb7b6754" />&nbsp;<img alt="page11image3882752" width="73.680000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9e29f380-8e0d-472c-8041-c873f7113cde" />&nbsp;<img alt="page11image3876416" width="106.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/218cbe87-486d-4df7-be47-4fdb890fed80" />&nbsp;<img alt="page11image3879104" width="116.760000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/43dd16e1-9373-4dda-b2db-0e9a183b2f45" /></p><p>General disorders and administration site conditions</p><p>Acute cholinergic syndrome<br />Common:&nbsp;Severe transient acute cholinergic syndrome was observed in 9 % of patients treated in monotherapy and in 1.4 % of patients treated in combination therapy. The main symptoms were defined as early diarrhoea and various other symptoms such as abdominal pain, conjunctivitis, rhinitis, hypotension, vasodilatation, sweating, chills, malaise, dizziness, visual disturbances, myosis, lachrimation and increased salivation occurring during or within the first 24 hours after the infusion of irinotecan hydrochloride trihydrate. These symptoms disappear after atropine administration (see section 4.4).</p><p>Asthenia was severe in less than 10 % of patients treated in monotherapy and in 6.2 % of patients treated in combination therapy. The causal relationship to irinotecan has not been clearly established.</p><p>Fever in the absence of infection and without concomitant severe neutropenia, occurred in 12 % of patients treated in monotherapy and in 6.2 % of patients treated in combination therapy.</p><p>Uncommon:&nbsp;Mild infusion site reactions have been reported. Cardiac disorders<br />Rare:&nbsp;Hypertension during or following the infusion. Respiratory, thoracic and mediastinal disorders</p><p>Uncommon:&nbsp;Interstitial pulmonary disease presenting as pulmonary infiltrates. Early effects such as dyspnoea have been reported (see section 4.4).</p><p>Skin and subcutaneous tissue disorders&nbsp;Very common:&nbsp;Reversible alopecia.&nbsp;Uncommon:&nbsp;Mild cutaneous reactions. Immune system disorders</p><p>Uncommon:&nbsp;Mild allergy reactions<br />Rare:&nbsp;Anaphylactic/anaphylactoid reactions.<br />Musculoskeletal and connective tissue disorders<br />Rare:&nbsp;Early effects such as muscular contraction or cramps and paresthesia have been reported. Investigations</p><p>Very Common:&nbsp;In combination therapy transient serum levels (grades 1 and 2) of either SGPT, SGOT, alkaline phosphatase or bilirubin were observed in 15 %, 11 %, 11 % and 10 % of the patients, respectively, in the absence of progressive liver metastasis. Transient grade 3 were observed in 0 %, 0 %, 0 % and 1 % of the patients, respectively. No grade 4 was observed.</p><p><img alt="page12image3831296" width="229.580000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/26c5b185-d663-4189-9190-8effce653643" />&nbsp;<img alt="page12image3831488" width="123.480000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/8284b258-ec44-43a5-a4ad-c58633e86a30" />&nbsp;<img alt="page12image3832640" width="77.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8b6889b6-c0e1-41ba-9975-78c0d407e1d9" />&nbsp;<img alt="page12image3833600" width="207.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/630483a9-ca71-40ce-ac6b-93f99a42716e" /><img alt="page12image3832832" width="171.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9083dc48-e690-4fe1-a041-b98be3041e70" />&nbsp;<img alt="page12image3833408" width="113.040000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/12ecd1bf-ea43-459b-8c82-3bc235739e76" />&nbsp;<img alt="page12image3826112" width="212.060000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/9a42deee-bb65-4f6c-8e14-501713d7e17b" />&nbsp;<img alt="page12image3833024" width="61.680000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/6a5fa9ec-3972-416a-992b-fdb96876670e" /></p><p>Common:&nbsp;In monotherapy, transient and mild to moderate increases in serum levels of either transaminases, alkaline phosphatase or bilirubin were observed in 9.2 %, 8.1 % and 1.8 % of the patients, respectively, in the absence of progressive liver metastasis. Transient and mild to moderate increases of serum levels of creatinine have been observed in 7.3 % of the patients.<br />Rare:&nbsp;Hypokalaemia and hyponatremia mostly related with diarrhoea and vomiting.</p><p>Very:&nbsp;Rare: Increases of amylase and/or lipase.<br />Nervous system disorders<br />Very rare:&nbsp;Transient speech disorders associated with infusion of irinotecan.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail:&nbsp;npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrhoea. There is no known antidote for irinotecan. Maximum supportive care should be instituted to prevent dehydration due to diarrhoea and to treat any infectious complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antinetoplastic agents, ATC Code: L01XX19. Experimental data</p><p>Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I. It is metabolised by carboxylesterase in most tissues to SN-38, which was found to be more active than irinotecan in purified topoisomerase I and more cytotoxic than irinotecan against several murine and human tumour cell lines. The inhibition of DNA topoisomerase I by irinotecan or SN-38 induces single-strand DNA lesions which blocks the DNA replication fork and are responsible for the cytotoxicity. This cytotoxic activity was found time-dependent and was specific to the S phase.</p><p>In vitro, irinotecan and SN-38 were not found to be significantly recognised by the P-glycoprotein MDR, and displays cytotoxic activities against doxorubicin and vinblastine resistant cell lines.</p><p>Furthermore, irinotecan has a broad antitumor activity&nbsp;in vivo&nbsp;against murine tumour models (P03 pancreatic ductal adenocarcinoma, MA16/C mammary adenocarcinoma, C38 and C51 colon</p><p><img alt="page13image3738048" width="113.760000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a37eb7e4-5aa4-4f59-91ee-6daf2df17a99" />&nbsp;<img alt="page13image3738432" width="180.260000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/8cd69a02-2349-4f90-8ac4-ad6512a047ab" />&nbsp;<img alt="page13image3738816" width="98.424000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e1e9164f-51cd-41b0-ab3b-4d6c28628497" />&nbsp;<img alt="page13image3738624" width="80.280000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e5d5fb3a-f3de-4cdf-9e4a-20e2be3cf205" /></p><p>adenocarcinomas) and against human xenografts (Co-4 colon adenocarcinoma, Mx-1 mammary adenocarcinoma, ST-15 and SC-16 gastric adenocarcinomas). Irinotecan is also active against tumors expressing the P-glycoprotein MDR (vincristine- and doxorubicin-resistant P388 leukaemia&#39;s).</p><p>Beside the antitumor activity of irinotecan, the most relevant pharmacological effect is the inhibition of acetylcholinesterase.</p><p>Clinical data</p><p>In monotherapy:&nbsp;Clinical phase II/III studies were performed in more than 980 patients in the every<br />3 week dosage schedule with metastatic colorectal cancer who failed a previous 5-FU regimen. The efficacy of irinotecan was evaluated in 765 patients with documented progression on 5-FU at study entry.</p><p><img alt="page14image3665536" width="55.920000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/ed81fe95-4328-424f-83c8-eaada53ebfec" /></p><p>Phase III Irinotecan versus supportive care</p><p>Irinotecan versus 5FU</p><p><img alt="page14image3668800" width="63.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/78ec6f78-fc6c-4360-91c7-80b565898ccf" />&nbsp;<img alt="page14image3666112" width="188.060000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/798eb73f-cf11-48c2-943b-0861a002b801" />&nbsp;<img alt="page14image3665152" width="172.970000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/a37f5200-391d-42aa-89f2-6eb72d320247" /></p><table><tbody><tr><td>&nbsp;</td><td><p>Irinotecan hydrochloride trihydrate</p><p>n=183</p></td><td><p>Supportive care</p><p>n=90</p></td><td><p>p values</p></td><td><p>Irinotecan hydrochloride trihydrate</p><p>n=127</p></td><td><p>5FU</p><p>n=129</p></td><td><p>p values</p></td></tr><tr><td><p>Progression Free Survival at 6 months (%)</p></td><td><p>NA</p></td><td><p>NA</p></td><td>&nbsp;</td><td><p>33.5*</p></td><td><p>26.7</p></td><td><p>p=0.03</p></td></tr></tbody></table><p>Survival at<br />12 months<br />(%)<br />Median<br />survival<br />(months)<br />NA: Non Applicable<br />* Statistically significant difference</p><p>p=0.0001 p=0.0001</p><p>44.8* 32.4 10.8* 8.5</p><p>p=0.0351 p=0.0351</p><p>36.2* 13.8 9.2* 6.5</p><p><img alt="page14image3855040" width="63.480000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/25e46a8c-7b0c-444d-8368-311a8458fd60" />&nbsp;<img alt="page14image3850624" width="73.344000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ba5e80da-1703-4170-9044-d321a3a1a283" />&nbsp;<img alt="page14image3852928" width="60.000000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0a97ec1d-e30d-4bc6-be6c-e2c0dddfa889" />&nbsp;<img alt="page14image3863104" width="54.000000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ae6cb1d1-55c9-49e8-a52f-a29e9b035c83" />&nbsp;<img alt="page14image3857536" width="73.464000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0ed0e5b8-ff38-4ab9-872e-7b62b06b043e" />&nbsp;<img alt="page14image3866176" width="44.640000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3edc112d-3256-43d0-9082-629b3c1f79a2" />&nbsp;<img alt="page14image3862912" width="53.904000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/021798df-fbb1-483b-a954-d20fd0bb85ae" />&nbsp;<img alt="page14image3855808" width="63.480000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fe660e46-9d79-4235-94d4-5782b46b04c7" />&nbsp;<img alt="page14image3852544" width="73.344000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/46d77a0f-9dce-4e8a-8149-fb55c0b2db61" />&nbsp;<img alt="page14image3858112" width="60.000000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9284ef6c-e49a-44fa-a288-e67d9b0d34e3" />&nbsp;<img alt="page14image3857920" width="54.000000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fcfee300-c2b1-49ca-bbe2-357caa7140cf" /><img alt="page14image3850240" width="73.464000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9bf80249-9336-4689-bbba-b35281f8aa87" />&nbsp;<img alt="page14image3850816" width="44.640000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f3d9db57-f409-4f4b-a9ad-fe88b683038b" />&nbsp;<img alt="page14image3851200" width="53.904000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fbc6f4db-a443-44d1-ace2-57c068bbd4c1" /></p><p>In phase II studies, performed on 455 patients in the every 3-week dosage schedule, the progression free survival at 6 months was 30 % and the median survival was 9 months. The median time to progression was 18 weeks.</p><p>Additionally, non-comparative phase II studies were performed in 304 patients treated with a weekly schedule regimen, at a dose of 125 mg/m2 administered as an intravenous infusion over 90 minutes for<br />4 consecutive weeks followed by 2 weeks rest. In these studies, the median time to progression was<br />17 weeks and median survival was 10 months. A similar safety profile has been observed in the weekly- dosage schedule in 193 patients at the starting dose of 125 mg/m2, compared to the every 3-week-dosage schedule. The median time of onset of the first liquid stool was on day 11.</p><p>In combination therapy:&nbsp;A phase III study was performed in 385 previously untreated metastatic colorectal cancer patients treated with either every 2 weeks schedule (see section 4.2) or weekly schedule</p><p>regimens. In the every 2 weeks schedule, on day 1, the administration of irinotecan hydrochloride trihydrate at 180 mg/m2 once every 2 weeks is followed by infusion with folinic acid (200 mg/m2 over a 2-hour intravenous infusion) and 5-fluorouracil (400 mg/m2 as an intravenous bolus, followed by<br />600 mg/m2 over a 22-hour intravenous infusion). On day 2, folinic acid and 5-fluorouracil are administered at the same doses and schedules. In the weekly schedule, the administration of irinotecan hydrochloride trihydrate at 80 mg/m2 is followed by infusion with folinic acid (500 mg/m2 over a 2-hour intravenous infusion) and then by 5-fluorouracil (2300 mg/m2 over a 24-hour intravenous infusion) over 6 weeks.<br />In the combination therapy trial with the 2 regimens described above, the efficacy of irinotecan was evaluated in 198 treated patients:</p><p><img alt="page15image3824576" width="82.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e0f14e3e-f71e-4d0f-8863-287b12bb3e30" />&nbsp;<img alt="page15image3825536" width="120.140000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/96f7368d-7f31-4af7-b792-9bb38a67076d" />&nbsp;<img alt="page15image3820736" width="119.900000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fbdcf516-e93d-40cd-8f8c-3677ac9773f2" />&nbsp;<img alt="page15image3820352" width="120.140000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/33dc0708-75de-403b-afa4-3ba6886d093b" /></p><p>Combined regimens (n=198)</p><p>Weekly schedule (n=50)</p><p>Every 2 weeks schedule (n=148)</p><table><tbody><tr><td>&nbsp;</td><td><p>Irinotecan hydrochloride trihydrate +5FU/FA</p></td><td><p>5FU/FA</p></td><td><p>Irinotecan hydrochloride trihydrate +5FU/FA</p></td><td><p>5FU/FA</p></td><td><p>Irinotecan hydrochloride trihydrate +5FU/FA</p></td><td><p>5FU/FA</p></td></tr></tbody></table><p>Response rate (%)</p><p>p value Median time to progression (months)<br />p value</p><p>p value</p><p>p value<br />Median time to<br />treatment<br />failure (months)<br />p value<br />Median survival<br />(months)<br />p value<br />5FU: 5-fluorouracil<br />FA: folinic acid<br />NS: Non Significant<br />*As per protocol population analysis</p><p>40.8* p&lt;0.001</p><p>6.7 p&lt;0.001</p><p>NS</p><p>23.1*</p><p>4.4</p><p>51.2* p=0.045</p><p>7.2</p><p>p=0.043</p><p>NS</p><p>NS NS</p><p>28.6*</p><p>6.5</p><p>37.5* p=0.005</p><p>21.6*</p><p><img alt="page15image3822656" width="82.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/50e47cde-466a-4fca-b2f0-86b4749facc6" />&nbsp;<img alt="page15image3817472" width="72.264000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/676389aa-24b4-4c3c-9972-e01a68ec6790" />&nbsp;<img alt="page15image3823232" width="47.400000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fc3ae442-8f53-4092-9165-d5cd8fbac886" />&nbsp;<img alt="page15image3819392" width="72.264000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9ac2a3a9-ef15-48e2-acec-463bd09f988f" />&nbsp;<img alt="page15image3822464" width="47.160000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/13c0411e-f021-4ac3-a389-21e39dbe3130" />&nbsp;<img alt="page15image3819008" width="72.240000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/acb6386d-03c8-4588-a41c-482923a22e09" />&nbsp;<img alt="page15image3821504" width="47.424000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/40734d77-0160-4ba1-9afd-95d31118a3ab" />&nbsp;<img alt="page15image3819968" width="82.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/dfbf22aa-ccf8-42a9-a843-217c177506fe" />&nbsp;<img alt="page15image3821120" width="72.264000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4d03879e-92c7-4c41-b663-19421f571105" />&nbsp;<img alt="page15image3821312" width="47.400000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/a575e04a-cbed-49c5-9bf7-1a48db0f2d32" />&nbsp;<img alt="page15image3821888" width="72.264000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/96cbaaf4-3e05-4cd1-82ed-338a35527e02" /><img alt="page15image3818240" width="47.160000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7d84b04e-6d4c-4c8e-983e-69928ce8bc6f" />&nbsp;<img alt="page15image3818816" width="72.240000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/55b3765e-0a4d-4048-aaab-afa391c3a180" />&nbsp;<img alt="page15image3817664" width="47.424000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/31b93051-665b-4398-ad31-77b32c9bedac" />&nbsp;<img alt="page15image3825728" width="82.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0a809044-f819-4642-b38a-248e9169e522" />&nbsp;<img alt="page15image3824384" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/02aa7278-6b8d-43f5-a9c6-86c2a1cc4271" />&nbsp;<img alt="page15image3823424" width="47.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/cdc1414e-70bf-415e-b8cb-d7e8738acaf4" />&nbsp;<img alt="page15image3820544" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/25d98943-636f-48e8-952f-7375a6cabf85" />&nbsp;<img alt="page15image3825920" width="47.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/18d966fe-3a71-4164-b9b8-a18950c819f2" />&nbsp;<img alt="page15image3822272" width="72.240000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1d4e8c88-cca9-4073-b325-da43ff28ca5a" />&nbsp;<img alt="page15image3820928" width="47.424000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/dd4855aa-2088-41eb-bc7e-a688ff7deb02" /></p><p>NS</p><p>6.5 3.7 p=0.001</p><p>NS</p><p>p=0.003<br />5.1 3.0</p><p>P&lt;0.001</p><p>15.6 13.0 p=0.041</p><table><tbody><tr><td><p>Median duration of response (months)</p></td><td><p>9.3</p></td><td><p>8.8</p></td><td><p>8.9</p></td><td><p>6.7</p></td><td><p>9.3</p></td><td><p>9.5</p></td></tr></tbody></table><table><tbody><tr><td><p>Median duration of response and stabilisation (months)</p></td><td><p>8.6</p></td><td><p>6.2</p></td><td><p>8.3</p></td><td><p>6.7</p></td><td><p>8.5</p></td><td><p>5.6</p></td></tr></tbody></table><p>p&lt;0.001 5.3</p><p>3.8</p><p>14.0</p><p>5.4</p><p>19.2</p><p>5.0</p><p>14.1</p><p><img alt="page15image3809344" width="82.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ab6844de-f13a-44c9-9cb0-ca4b4a4f69aa" />&nbsp;<img alt="page15image3809152" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ed177033-b443-47b7-89f2-c8b8ce8f0720" />&nbsp;<img alt="page15image3804544" width="47.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9db3e2fb-92eb-4cab-89e1-d7feebf76733" />&nbsp;<img alt="page15image3801088" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d664f932-3746-45ae-bfda-1a92599241b6" />&nbsp;<img alt="page15image3801664" width="47.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/da4c3e04-4539-41e9-9070-ad735363df25" />&nbsp;<img alt="page15image3803200" width="72.240000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/641d36b7-0f19-4156-92bb-077f7bdf3bbd" />&nbsp;<img alt="page15image3806848" width="47.424000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4d53c25b-105e-4c0d-83e2-231ba0f6efe8" />&nbsp;<img alt="page15image3806272" width="82.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2de19ab4-2898-4222-9f7f-5f318f36041d" />&nbsp;<img alt="page15image3802240" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a277b790-b78c-4001-99d3-33e133970492" />&nbsp;<img alt="page15image3802048" width="47.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8d809272-fd19-46f0-9584-5bda950bffcf" />&nbsp;<img alt="page15image3801280" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/84b49ab7-eda3-4c39-a421-96d57a6246dc" /><img alt="page15image3804928" width="47.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f4b4403a-1ae9-483c-9b9f-6f5ad15a973a" />&nbsp;<img alt="page15image3805312" width="72.240000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e5b48b61-09f4-4a1c-9948-5e184c239b83" />&nbsp;<img alt="page15image3802816" width="47.424000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b7aec9e9-914d-4c38-a838-a8e9ca729228" /></p><p>p=0.0014</p><p><img alt="page15image3804160" width="82.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/1eff0ac8-2e04-4ca4-b77f-4c56e8ef433c" />&nbsp;<img alt="page15image3806656" width="72.264000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/03918866-7b39-4722-96dc-09859ee21673" />&nbsp;<img alt="page15image3805120" width="47.400000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/e91980e2-9081-4e34-9fa5-89fb62a87c45" />&nbsp;<img alt="page15image3805696" width="72.264000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/d12661bc-75b7-4718-a6cc-d1c1e5612582" />&nbsp;<img alt="page15image3805504" width="47.160000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/5131c9ee-59fb-4572-8216-1ca97a862425" />&nbsp;<img alt="page15image3806464" width="72.240000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/20d621a0-6a42-4752-ac67-f3462b361860" />&nbsp;<img alt="page15image3807040" width="47.424000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/2daa29e6-4d1f-4dcf-8319-6e69f389d5e5" /></p><p>16.8 p=0.028</p><p><img alt="page15image3807424" width="82.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1e639177-4271-457f-b3ea-d7d5d0665089" />&nbsp;<img alt="page15image3807232" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5749f065-6fb6-4dba-82c5-a190ee6aa3c5" />&nbsp;<img alt="page15image3807616" width="47.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a2cb5919-025f-45ec-ba95-364c56b3322a" />&nbsp;<img alt="page15image3807808" width="72.264000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ff2282bd-afa1-424f-a4bf-fa7960fc4265" />&nbsp;<img alt="page15image3808192" width="47.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/53c2cfd3-c2a0-46b1-8f60-53ba65b580d9" />&nbsp;<img alt="page15image3808000" width="72.240000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/16e88916-4065-467d-8630-5853b22456fa" />&nbsp;<img alt="page15image3803584" width="47.424000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/56acca3a-e182-41ef-8864-99a9042c6ed1" />&nbsp;<img alt="page15image3808576" width="82.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c5cf21f1-baa9-4126-8e32-5635258eeb72" />&nbsp;<img alt="page15image3809728" width="120.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1f16a0a8-21ff-4927-80c6-57aa9b9f884e" /><img alt="page15image3808384" width="119.900000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1469a923-f54f-46ae-ae4f-2fbcd8826d20" />&nbsp;<img alt="page15image3810304" width="120.140000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/560fc210-43c0-4a2c-be40-7accd90f2591" /></p><p>In the weekly schedule, the incidence of severe diarrhoea was 44.4 % in patients treated by irinotecan in combination with 5FU/FA and 25.6 % in patients treated by 5FU/FA alone. The incidence of severe neutropenia (neutrophil count &lt; 500 cells/mm3) was 5.8 % in patients treated by irinotecan in combination with 5FU/FA and in 2.4 % in patients treated by 5FU/FA alone.</p><p>Additionally, median time to definitive performance status deterioration was significantly longer in irinotecan combination group than in 5FU/FA alone group (p=0.046).</p><p>Quality of life was assessed in this phase III study using the EORTC QLQ-C30 questionnaire. Time to definitive deterioration constantly occurred later in the irinotecan groups. The evolution of the Global Health Status/Quality of life was slightly better in irinotecan combination group although not significant, showing that efficacy of irinotecan in combination could be reached without affecting the quality of life.</p><p>In combination with cetuximab:</p><p>The efficacy of the combination of cetuximab with irinotecan was investigated in two clinical studies. A total of 356 patients with EGFR-expressing metastatic colorectal cancer who had recently failed irinotecan including cytotoxic therapy and who had a minimum Karnofsky performance status of 60, but&nbsp;the majority of whom had a Karnofsky performance status of &ge;&nbsp;80 received the combination treatment. EMR 62 202-007: This randomised study compared the combination of cetuximab and irinotecan</p><p>(218 patients) with cetuximab monotherapy (111 patients).<br />IMCL CP02-9923: This single arm open-label study investigated the combination therapy in 138 patients. The efficacy data from these studies are summarised in the table below:</p><p><img alt="page16image3835584" width="42.720000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c797af0a-ff08-413c-b0cb-7198a7dda35d" />&nbsp;<img alt="page16image3845568" width="92.784000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7ef34998-904b-4fed-8b38-03a012b205b6" />&nbsp;<img alt="page16image3847104" width="92.904000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/22cd93b3-c36a-47a4-9f36-985e924eaa7c" />&nbsp;<img alt="page16image3836160" width="102.000000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/aae47da7-6950-4889-9317-229bbac2dbd3" />&nbsp;<img alt="page16image3842304" width="101.660000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/fe635d07-b079-4a34-b4f4-f58c6640b1cc" />&nbsp;<img alt="page16image3835200" width="41.640000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3052157f-c7cc-4ba7-a655-6947dcbbc7ab" />&nbsp;<img alt="page16image3838464" width="92.064000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/63c9a184-b534-4133-9b81-7b9bc4ae99a3" />&nbsp;<img alt="page16image3835968" width="91.944000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a4b93e1a-c88c-491b-b48c-1914921ec7e4" /><img alt="page16image3849600" width="101.280000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/66b0dd44-0b11-44c1-bf45-c3b6a76f2426" />&nbsp;<img alt="page16image3838656" width="101.300000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/648a717a-37e0-4f7a-bdb6-82388e5dd1c2" /></p><p>Study N ORR DCR PFS (months)<br />n (%) 95%CI n (%) 95%CI Median 95%CI</p><p>Cetuximab + irinotecan</p><p>Cetuximab</p><p>111</p><p>OS (months) Median 95%CI</p><p><img alt="page16image3835392" width="41.640000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9d7d5df3-41f1-4af3-8804-ca3ad82d0553" />&nbsp;<img alt="page16image3845952" width="92.064000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/35d1fbec-1fbc-478a-bd15-845cc20f5ada" />&nbsp;<img alt="page16image3834048" width="91.944000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/8982702f-0a67-4655-ada9-9003ae7fb3e1" />&nbsp;<img alt="page16image3843648" width="101.280000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/4a34fe0c-3bf4-4518-9992-fc2c38f3dbe1" />&nbsp;<img alt="page16image3837504" width="101.300000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/52bdb95d-5400-450f-9c2d-102090be0dc4" />&nbsp;<img alt="page16image3843456" width="41.640000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5bae5515-6cda-44e7-ab13-5c8750e41c59" />&nbsp;<img alt="page16image3844416" width="41.040000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/cb98cdb9-84e7-426b-807f-13e9614ec585" />&nbsp;<img alt="page16image3843264" width="49.464000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e6d9721d-9d3c-47f0-b3b0-44f07a2c510e" />&nbsp;<img alt="page16image3839808" width="40.920000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/bdb77e91-93bc-4bfc-b0ca-50210ed2a66b" />&nbsp;<img alt="page16image3844800" width="49.464000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7129dd2f-9ad6-430e-bc5c-ec205f416004" />&nbsp;<img alt="page16image3837888" width="50.280000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/cf0325c1-2565-46e0-a943-5602cba11994" /><img alt="page16image3846144" width="49.560000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0d270df5-5723-418f-8ca0-0d256019ec22" />&nbsp;<img alt="page16image3844992" width="50.304000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d2f18005-4eaf-44d0-a242-4d0582c5437e" />&nbsp;<img alt="page16image3841920" width="49.560000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/06e3ed7a-f222-4889-be4a-ca640a35f778" />&nbsp;<img alt="page16image3849216" width="41.640000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e0430640-c67b-4dd1-bc54-912725beac90" />&nbsp;<img alt="page16image3835776" width="41.040000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c0181f2e-6ff9-4c0a-ab04-2ae5f2627bf2" />&nbsp;<img alt="page16image3847296" width="49.464000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/410b1d89-046f-4247-b39a-8b18740a57a8" />&nbsp;<img alt="page16image3848448" width="40.920000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6d126ed5-7247-4828-ae7f-945d080f0c66" />&nbsp;<img alt="page16image3842112" width="49.464000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/b2472e85-e2e8-4fe0-a83b-b75fbd42c9dc" />&nbsp;<img alt="page16image3834624" width="50.280000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/18f57b9e-f4aa-4058-bfa7-7403f2ff78b8" />&nbsp;<img alt="page16image3840768" width="49.560000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/edf86257-78f3-4b09-9b23-66ebbc1a0d4f" />&nbsp;<img alt="page16image3849984" width="50.304000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3718a41a-3934-48fe-9a92-294dc4184990" />&nbsp;<img alt="page16image3839424" width="49.560000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f13b48bf-6ff9-4e6e-afe6-80eea18392fb" /><img alt="page16image3843840" width="463.030000" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2f6d169b-64c0-4eeb-8cac-e070cfdf0585" /></p><table><tbody><tr><td><p>EMR 62 202- 007</p></td><td rowspan="2" colspan="1"><p>218 138</p></td><td><p>50 (22.9)</p></td><td><p>17.5, 29.1</p></td><td><p>121 (55.5)</p></td><td><p>48.6, 62.2</p></td><td><p>4.1</p></td><td><p>2.8, 4.3</p></td><td><p>8.6</p></td><td><p>7.6, 9.6</p></td></tr><tr><td><p>IMCL CP02- 9923</p></td><td><p>21 (15.2)</p></td><td><p>9.7, 22.3</p></td><td><p>84 (60.9)</p></td><td><p>52.2, 69.1</p></td><td><p>2.9</p></td><td><p>2.6, 4.1</p></td><td><p>8.4</p></td><td><p>7.2, 10.3</p></td></tr></tbody></table><p><img alt="page16image3796800" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/44f0a22d-2756-417a-af45-f3f1e3c8081c" />&nbsp;<img alt="page16image3796992" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/8768aa62-ca25-4e80-9b7d-29665b1ba9d6" />&nbsp;<img alt="page16image3797184" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/61899c5c-6dea-4770-915f-4adfdc7a6f11" />&nbsp;<img alt="page16image3797376" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/152c2ba3-43db-479d-aeb3-dd62a8efd28c" />&nbsp;<img alt="page16image3797568" width="0.719970" height="43.944000" src="blob:https://sdi.sfda.gov.sa/674d8b84-0d5c-4913-a66d-948f4193f081" />&nbsp;<img alt="page16image3797760" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/871551b1-d871-4fe9-bc1a-b338b53f1b48" />&nbsp;<img alt="page16image3797952" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/e6fed851-19eb-4606-b136-7a01a114f68a" />&nbsp;<img alt="page16image3798144" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/c7041d00-be88-48cd-b22b-66406c392af6" />&nbsp;<img alt="page16image3798336" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/cdfe2132-9e73-42b7-8c07-4dcd1b51746a" />&nbsp;<img alt="page16image30526416" width="50.280000" height="44.664000" src="blob:https://sdi.sfda.gov.sa/2247cdc6-4d97-4ef1-abc6-62c1ed5afe3b" />&nbsp;<img alt="page16image3798912" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/17c1f8fa-8e69-4758-9bb7-df8a8b17a713" />&nbsp;<img alt="page16image3799104" width="0.720000" height="43.944000" src="blob:https://sdi.sfda.gov.sa/58d1d525-98cf-4a82-b577-baed99864b2f" />&nbsp;<img alt="page16image3799296" width="0.719970" height="43.944000" src="blob:https://sdi.sfda.gov.sa/a9de9df0-1679-48f4-b2e3-cfc38ec83b43" />&nbsp;<img alt="page16image30531904" width="50.280000" height="44.664000" src="blob:https://sdi.sfda.gov.sa/d0d2c5da-332b-4f78-b2f9-834f14daf8a9" /></p><p>EMR 62 202- 007</p><p>12 (10.8)</p><p>5.7, 18.1</p><p>36 (32.4)</p><p>23.9, 42.0</p><p>1.5</p><p>1.4, 2.0</p><p>6.9</p><p>5.6, 9.1</p><p>CI = confidence interval, DCR = disease control rate (patients with complete response, partial response, or stable disease for at least 6 weeks), ORR = objective response rate (patients with complete response or partial response), OS = overall survival time, PFS = progression-free survival.<br />The efficacy of the combination of cetuximab with irinotecan was superior to that of Cetuximab monotherapy, in terms of objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS). In the randomised trial, no effects on overall survival were demonstrated (hazard ratio 0.91, p = 0.48).</p><p>In combination with bevacizumab:</p><p>A phase III randomised, double-blind, active-controlled clinical trial evaluated bevacizumab in combination with irinotecan /5FU/FA as first-line treatment for metastatic carcinoma of the colon or rectum (Study AVF2107g). The addition of bevacizumab to the combination of irinotecan /5FU/FA resulted in a statistically significant increase in overall survival. The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved, and duration of metastatic disease. Refer also to the bevacizumab summary of product characteristics. The efficacy results of Study AVF2107g are summarized in the table below.</p><p><img alt="page17image3509248" width="165.740000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/fdd380f8-d150-4cb6-bbd6-cb836b726c61" />&nbsp;<img alt="page17image3515200" width="204.770000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7c341a01-e27f-4902-9ea2-067e6c22d9ce" /></p><p>AVF2107g</p><p><img alt="page17image3510592" width="100.340000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/83f2912b-6a73-4e28-98b5-7b5f9c2132c4" />&nbsp;<img alt="page17image3507136" width="103.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c7a26657-b1f3-49f1-b47f-d9cb50ba6b8f" />&nbsp;<img alt="page17image3510400" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1e52da25-b1fc-4273-9ae5-2b57ba342ee0" />&nbsp;<img alt="page17image3507520" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/de099c1b-736a-4e1a-af2e-64672250eb17" />&nbsp;<img alt="page17image3515584" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/39a77f94-2bb3-4f72-bb49-776d87d8d33d" /></p><p>Number of Patients Overall survival</p><p>Median time (months) 95% Confidence Interval</p><p>Hazard ratiob</p><p>p-value Progression-free survival</p><p>Median time (months) Hazard ratio<br />p-value</p><p>Overall response rate Rate (%)</p><p>95% CI</p><p>p-value Duration of response</p><p>Median time (months)</p><p>25&ndash;75 percentile (months)&nbsp;a5 mg/kg every 2 weeks.</p><p>bRelative to control arm. Pharmacokinetic/Pharmacodynamic data</p><p>Arm 1&nbsp;irinotecan&nbsp;/5FU/FA + Placebo<br />411</p><p>15.6 14.29&nbsp;&ndash;&nbsp;16.99</p><p>6.2</p><p>34.8 30.2&nbsp;&ndash;&nbsp;39.6</p><p>7.1 4.7&nbsp;&ndash;&nbsp;11.8</p><p>Arm 2&nbsp;irinotecan&nbsp;/5FU/FA + Avastina<br />402</p><p>20.3 18.46&nbsp;&ndash;&nbsp;24.18 0.660 0.00004</p><p>10.6</p><p>0.54<br />&lt; 0.0001</p><p>44.8 39.9&nbsp;&ndash;&nbsp;49.8 0.0036</p><p>10.4 6.7&nbsp;&ndash;&nbsp;15.0</p><p><img alt="page17image3510784" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/947dd2b4-0f16-47c9-8ab3-9349a1da7fa7" />&nbsp;<img alt="page17image3506368" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7295b4ad-3bb0-42f6-ad2a-453df6d33bba" />&nbsp;<img alt="page17image3517696" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f6796194-f2b3-4c05-a743-f08ef4bc4187" />&nbsp;<img alt="page17image3520384" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8e5bc1ab-470b-4eab-9ce5-91b5c21e5190" />&nbsp;<img alt="page17image3516544" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c9ec731a-88fa-4a62-9747-c56ad1ba4003" />&nbsp;<img alt="page17image3519040" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6e29c9e2-0b55-46d9-ad6a-3b3eaf2bf355" /><img alt="page17image3520192" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c5ae576b-4c0c-4851-afb7-63e53dd03d5e" />&nbsp;<img alt="page17image3519808" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a4844d3f-91eb-45a2-a66c-8dc2bba9020a" />&nbsp;<img alt="page17image3507712" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3d8c850b-0f3f-452b-8773-ded467c623fb" />&nbsp;<img alt="page17image3518272" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/76aa7fba-41bb-4e67-814a-5c05e817f18a" />&nbsp;<img alt="page17image3507904" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/70ff27cc-d097-4579-8435-071d35777da7" />&nbsp;<img alt="page17image3510016" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/62a482a2-2860-4901-9a55-dfbd4636ec9d" /><img alt="page17image3521728" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e47e76d6-085b-4baa-b4d3-103c6aaf0741" />&nbsp;<img alt="page17image3518464" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/24f3272a-e203-4ce1-a74f-547ac61fbb73" />&nbsp;<img alt="page17image3512704" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/62c38d60-01d1-4486-982d-6a0b37a1bed7" />&nbsp;<img alt="page17image3521152" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/336ed46f-56e2-4b92-a208-30e743d415c3" />&nbsp;<img alt="page17image3521344" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6cfca656-1ec6-4134-a856-3168ae399335" />&nbsp;<img alt="page17image3516736" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d8a450d0-8bda-45fa-a9ad-2eda942e29ce" /><img alt="page17image3513472" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/31f25a25-15d6-4975-8e6f-f953883ea039" />&nbsp;<img alt="page17image3512512" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8b6bb96d-e2fe-42de-8a85-de2540e6309b" />&nbsp;<img alt="page17image3506176" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/167cab32-d0b3-4009-8170-7ba01dd3e676" />&nbsp;<img alt="page17image3537344" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/60f7561d-a22e-4aea-94c5-887cb9b0b82e" />&nbsp;<img alt="page17image3536576" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3831233b-6d0c-435c-8343-e591ac10519a" />&nbsp;<img alt="page17image3536192" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7394bcec-59f4-4f8e-81c7-d8a64c8d571a" /><img alt="page17image3537536" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/04fc69f9-4d56-42f6-b14b-8b6a8e15fd9c" />&nbsp;<img alt="page17image3538304" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4036696d-8f7f-4652-9b79-db66807119ac" />&nbsp;<img alt="page17image3537920" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0a193301-1f0d-4f53-83a4-38ee8f5f7d95" />&nbsp;<img alt="page17image3537728" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3e60b07c-4846-4548-beb1-89df099bdf8b" />&nbsp;<img alt="page17image3535808" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1e6ea75a-c479-4065-9e18-fcc3d19a0523" />&nbsp;<img alt="page17image3525440" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2560e6f4-e5bf-4b68-a2c0-732810c05572" /><img alt="page17image3524288" width="165.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3c8f6516-4b2b-4be3-8643-c0494eb84abd" />&nbsp;<img alt="page17image3528704" width="100.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8e4421bb-c3af-4e59-837c-6bd61644f783" />&nbsp;<img alt="page17image3533504" width="103.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/37f1c57e-7c07-4310-a52c-fea1ba93520c" />&nbsp;<img alt="page17image3523136" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/a3f025e1-2f8d-42c5-adbb-5ea5056a7585" />&nbsp;<img alt="page17image3533312" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/5940836b-b199-4b39-b5a6-ba30c559ef80" />&nbsp;<img alt="page17image3531584" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d5c6dec3-7bc4-4fb4-ba28-f60a82038ec2" /><img alt="page17image3523328" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e407c97b-0e7c-4d4d-a452-f7df3ef3ce4b" />&nbsp;<img alt="page17image3531968" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c1520e4d-88d1-4f3a-9145-5a9dd1709fb3" />&nbsp;<img alt="page17image3527168" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d51d542d-e137-4a58-a032-0bfea40e8c41" />&nbsp;<img alt="page17image3524864" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/a70aac58-f323-467f-a689-b3ac7dd7a7b9" />&nbsp;<img alt="page17image3523520" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7c29221b-9e33-4b2b-bc64-27655e1861f4" />&nbsp;<img alt="page17image3528320" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e1381a9d-d469-4548-a21c-1c4dda43999e" /><img alt="page17image3527936" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2fd17e79-6919-4314-9072-c9c4f16e1b81" />&nbsp;<img alt="page17image3525248" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1dc26b15-57dc-4f61-9246-8022c03dd2a1" />&nbsp;<img alt="page17image3525632" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e6dc1a0f-437a-4d04-9fce-6d34c8dd1112" />&nbsp;<img alt="page17image3529280" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/28526dd1-52e9-454b-a69e-4c0dfd07e9d4" />&nbsp;<img alt="page17image3525056" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e151d7d6-e2c2-4773-bf46-9d8c95143e0d" />&nbsp;<img alt="page17image3528128" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ee433767-ca59-455b-a07b-02128cbac85b" /><img alt="page17image3527552" width="165.740000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4e86ac35-787a-4db4-b4f3-654034b13aef" />&nbsp;<img alt="page17image3529088" width="100.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e0f70872-4b52-48fc-bfec-7ba302a004dd" />&nbsp;<img alt="page17image3529664" width="103.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f7758e03-f0f6-4d11-84ad-cf5be6d3adb0" />&nbsp;<img alt="page17image3522944" width="179.900000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f9732309-04e5-4002-bd4c-a6d23f568003" /></p><p>The intensity of the major toxicities encountered with irinotecan (e.g., leukoneutropenia and diarrhoea) are related to the exposure (AUC) to parent drug and metabolite SN-38. Significant correlations were observed between haematological toxicity (decrease in white blood cells and neutrophils at nadir) or diarrhoea intensity and both irinotecan and metabolite SN-38 AUC values in monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a phase I study in 60 patients with a dosage regimen of a 30-minute intravenous infusion of 100 to<br />750 mg/m2 every three weeks, irinotecan showed a biphasic or triphasic elimination profile. The mean plasma clearance was 15 L/h/m2 and the volume of distribution at steady state (Vss): 157 L/m2. The mean plasma half-life of the first phase of the triphasic model was 12 minutes, of the second phase 2.5 hours,</p><p>and the terminal phase half-life was 14.2 hours. SN-38 showed a biphasic elimination profile with a mean terminal elimination half-life of 13.8 hours. At the end of the infusion, at the recommended dose of<br />350 mg/m2, the mean peak plasma concentrations of irinotecan and SN-38 were 7.7 &mu;g/ml and 56 ng/ml, respectively, and the mean area under the curve (AUC) values were 34 &mu;g.h/ml and 451 ng.h/ml, respectively. A large interindividual variability in pharmacokinetic parameters is generally observed for SN-38.</p><p>A population pharmacokinetic analysis of irinotecan has been performed in 148 patients with metastatic colorectal cancer, treated with various schedules and at different doses in phase II trials. Pharmacokinetic parameters estimated with a three compartment model were similar to those observed in phase I studies. All studies have shown that irinotecan (CPT-11) and SN-38 exposure increase proportionally with CPT- 11 administered dose; their pharmacokinetics are independent of the number of previous cycles and of the administration schedule.</p><p>In vitro, plasma protein binding for irinotecan and SN-38 was approximately 65 % and 95 % respectively.</p><p>Mass balance and metabolism studies with 14 C-labelled drug have shown that more than 50 % of an intravenously administered dose of irinotecan is excreted as unchanged drug, with 33 % in the faeces mainly via the bile and 22 % in urine.</p><p>Two metabolic pathways account each for at least 12 % of the dose:<br />&bull; Hydrolysis by carboxylesterase into active metabolite SN-38. SN-38 is mainly eliminated by glucuronidation, and further by biliary and renal excretion (less than 0.5 % of the irinotecan dose) The SN-38 glucuronite is subsequently probably hydrolysed in the intestine.<br />&bull; Cytochrome P450 3A enzymes-dependent oxidations resulting in opening of the outer piperidine ring with formation of APC (aminopentanoic acid derivate) and NPC (primary amine derivate) (see section 4.5).</p><p>Unchanged irinotecan is the major entity in plasma, followed by APC, SN-38 glucuronide and SN-38. Only SN-38 has significant cytotoxic activity.</p><p>Irinotecan clearance is decreased by about 40 % in patients with bilirubinemia between 1.5 and 3 times the ULN. In these patients a 200 mg/m2 irinotecan dose leads to plasma drug exposure comparable to that observed at 350 mg/m2 in cancer patients with normal liver parameters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irinotecan and SN-38 have been shown to be mutagenic&nbsp;in vitro&nbsp;in the chromosomal aberration test on CHO-cells as well as in the&nbsp;in vivo&nbsp;micronucleus test in mice. However, they have been shown to be devoid of any mutagenic potential in the Ames test.</p><p>In rats treated once a week during 13 weeks at the maximum dose of 150 mg/m2 (which is less than half the human recommended dose), no treatment related tumours were reported 91 weeks after the end of treatment.</p><p>Single- and repeated-dose toxicity studies with irinotecan have been carried out in mice, rats and dogs. The main toxic effects were seen in the haematopoietic and lymphatic systems. In dogs, delayed diarrhoea associated with atrophy and focal necrosis of the intestinal mucosa was reported. Alopecia was also observed in the dog. The severity of these effects was dose-related and reversible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sorbitol E420<br />Lactic Acid<br />Sodium Hydroxide (to pH 3.5)</p><p>Hydrochloric acid (to pH 3.5 when needed)</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products, except those mentioned in section 6.6 (see also section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial before opening
3 years.
After opening
The content of the vial should be used immediately after the first breakage of vial.
After dilution
Chemical and physical in-use stability of the drug product after dilution in the recommended solutions for infusion (see section 6.6) has been demonstrated for 24 hours at 30°C and for 48 hours at 2-8°C.
From a microbiological point of view, unless the methods of opening and dilution preclude the risk of microbial contamination, the product should be used immediately after dilution.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light.<br />Do not freeze.<br />For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Brown glass vial (type I) with bromobutylic rubber stopper and metallic cap (aluminium) with polypropylene disk. Vials may or may not be sheathed in protective sleeve.</p><p>Pack sizes</p><p>1 x 2 ml vial 1 x 5 ml vial 5 x 5 ml vial 1 x 15 ml vial 1 x 25 ml vial</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Handling<br />As with all antineoplastic agents, caution should be exercised when handling Tecana. Dilution should be carried out under aseptic conditions by trained personnel in a designated area. Precautions should be taken to avoid contact with the skin and mucous membranes.</p><p>Instructions for dilution<br />Tecana concentrate for solution for infusion is intended for intravenous infusion only after diluting prior to administration in the recommended diluents, either 0.9 % Sodium chloride solution for infusion or 5 % glucose solution for infusion. Aseptically withdraw the required amount of Tecana concentrate for solution from the vial with a calibrated syringe and inject into a 250 ml infusion bag or bottle. The infusion should be thoroughly mixed by manual rotation.</p><p>If any precipitate is observed in the vials or after reconstitution, the product should be discarded according to standard procedures for cytotoxic agents.</p><p>Protection instructions for preparation of Tecana solution for infusion</p><ol><li><p>Protective chamber should be used and protective gloves as well as protective gown should be</p><p>worn. If there is no protective chamber available mouth cover and goggles should be used.</p></li><li><p>Opened containers, like injection vials and infusion bottles and used cannulae, syringes, catheters,</p><p>tubes, and residuals of cytostatics should be considered as hazardous waste and undergo disposal</p><p>according to local guidelines for the handling of HAZARDOUS WASTE.</p></li><li><p>Follow the instructions below in case of spillage:</p><p>- protective clothing should be worn<br />- broken glass should be collected and placed in the container for HAZARDOUS WASTE - contaminated surfaces should be flushed properly with copious amounts of cold water<br />- the flushed surfaces should then be wiped thoroughly and the materials used for wiping</p><p>should be disposed as HAZARDOUS WASTE</p></li><li><p>In the event of Tecana contact with the skin, the area should be rinsed with plenty of running water</p><p>and then washed with soap and water. In case of contact with mucous membranes, wash the</p><p>contacted area thoroughly with water. If you have any discomfort, contact a doctor.</p></li><li><p>In case of contact of Tecana with eyes, wash them thoroughly with plenty of water. Contact an</p><p>ophthalmologist immediately.</p></li></ol><p>Disposal<br />All items used for preparation, administration or otherwise coming into contact with irinotecan should undergo disposal according to local guidelines for the handling of cytotoxic compounds.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actavis Group hf. Reykjavíkurvegi 76-78 IS-220 Hafnarfjörður Iceland

Tdawi Biomedical 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>